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The total synthesis of marineosin A, a unique spiroaminal with selective cytotoxicity, has been 
under investigation in our laboratory. A ruthenium-catalyzed enolate allylic alkylation 
methodology and azafulvene dimer-derived metathesis strategy have been considered as 
potential routes, towards the synthesis of the macrocyclic core of marineosin A.   
 
A novel route to the synthesis of diverse pyrrolidine scaffolds, for diversity-oriented synthesis 
has additionally been under investigation in our laboratory.  The synthetic route encompasses a 
series of reductive amination, iodocyclization, azide substitution, and reductive deprotection to 
deliver the target diamine scaffolds in 14-16% yield. In addition, an asymmetric approach to the 
synthesis of (2S,3R,4R)-β–iodo amine has been presented, which takes advantage of selective 
Ru(II)-catalyzed Claisen rearrangement methodology.  
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1.0  INTRODUCTION 
1.1 BIOLOGICAL ACTIVITY AND STRUCTURAL FEATURES 
Terrestrial bacteria within the order Actinomycetales have historically demonstrated a prolific 
ability to generate thousands of small molecule natural products. These compounds from 
terrestrial sources have included clinically useful antibiotics, anticancer agents and 
immunosuppressive agents.
1
 Amongst the most useful soil-derived genera, Streptomyces and 
Micromonospora account for the vast majority of microbial antibiotics discovered.
2
 Although the 
genus Streptomyces is generally associated with terrestrial soils, marine soil bacteria that require 
seawater for growth have become increasingly important sources of novel secondary metabolites. 
These marine actinomycetes that display distinct phylotypes, are unrelated to strains previously 
discovered on land or in the sea. Targeted screening has revealed secondary metabolites such as 
marinomycin A (1), marinone (2) and salinosporamide C (3) with substantial activities against 
selected human tumors and drug-resistant bacterial pathogens (Figure 1).
3,4,5 
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Figure 1. Representative structures of natural products isolated from marine actinomycetes 
 
Marineosins A and B (4, 5), are two novel compounds originally isolated from cultures of 
sediment-derived marine actinomycetes, related to the genus Streptomyces (Figure 2).
6
  These 
unique spiroaminals were first identified by Fenical and coworkers in 2008. Biosynthetically, 4 
and 5 are thought to have derived from a prodigiosin-like class of bacterial pigments. These 
features are highlighted by the presence of a bis-pyrrole functionality typified by 
undecylprodigiosin (6). However, the spiro-tetrahydropyran-dihydropyrrole aminal ring systems 
of the marineosins is unprecedented and believed to arise from a modification within the pigment 
pathway.
7
 Structurally, marineosin A (4) and B (5) differ at both C7 and C8 stereocenters, a 
feature which results in substantially different cytotoxic activities. The major isomer, marineosin 
A (4) displayed inhibition of human colon carcinoma HCT-116 with an IC50 of 0.5 µM.  In 
contrast, marineosin B (5) displays considerably weaker cytotoxicity with an IC50 of 46 µM.  
Furthermore, testing of marineosin A (4) in a NCI 60 cell line panel indicated a broad 
cytotoxicity with selectivity against melanoma and leukemia cell lines (Figure 2).
6,8,9 
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Figure 2. Structures of marineosins A (4) and B (5) and undecylprodigiosin (6) 
 
Fenical and co-workers have also proposed a possible biosynthesis of 4 and 5. The 
envisioned route involves known 4-methoxy-2,2’-bipyrrole-5-carbaldehyde (7), a key 
intermediate in the biosynthetic pathway of  prodigiosin-like pigments, and relies on a potential 
inverse-electron-demand hetero-Diels-Alder cycloaddition to deliver the core marineosin 
structure (Figure 3).
6
 An alternative biosynthesis of the marineosins has additionally been 
proposed by Snider based on sequencing data of the gene cluster responsible for the biosynthesis 
of undecylprodigiosin (6) in Streptomyces coelicolor.
10
 The alternative route takes advantage of 
nonheme iron-dependent dioxygenases to initiate and sequester radicals throughout the pathway 
(Figure 2).
9
  
1.2 PREVIOUS EFFORTS DIRECTED TOWARDS THE TOTAL SYNTHESIS OF 
MARINEOSINS A AND B  
The biomimetic syntheses initially proposed by Fenical and Snider, have recently been 
evaluated. These preliminary efforts have focused primarily on key transformations en route to 
marineosins A (4) and B (5). More recently, Lindsley and Shi have investigated synthetic 
 4 
strategies based upon model systems of the 12-membered macrocyclic core and spiroiminal 
fragments of these natural products. 
11,12,13
 
1.2.1 Evaluation of Proposed Biosyntheses 
Fenical’s proposal shown in Figure 3, centers on the conversion of 9 to 10 via an intramolecular 
hetero-Diels-Alder reaction to simultaneously form both the dihydropyran ring and spiroaminal 
functionality. The hypothesized biosynthetic C1-C25 Diels-Alder substrate (9) was thought to 
result from a direct condensation of C1-C9 4-methoxy-2, 2’-bipyrrole-5-carbaldehyde (7) and the 
enone containing C10- C24 pyrrole 8. Common to the biosynthetic pathway of prodigiosins, 
bipyrrole 7 has previously been demonstrated through feeding studies to be derived from proline, 
serine, glycine and several additional acetate subunits. Similar to Fenical’s proposal the known 
biosynthesis of prodigiosins is convergent often involving late-stage condensation with 
substituted pyrroles. A diastereomeric mixture of 4 and 5 can therefore be explained by 
visualizing the ensuing cyclization occurring from above and below the plane of enone 9.
6
 A 
detailed account of subsequent steps towards the total synthesis of marineosin A and B have not 
been previously reported.  
 5 
 
Figure 3. Fenical’s proposed biosynthesis 
 
In order to investigate this proposed biosynthesis, Lindsley and coworkers further 
developed a retrosynthetic analysis based upon Fenical’s design. The analysis commences with a 
hetero-Diels-Alder cycloaddition to generate 10, followed by acid-mediated condensation of 
bipyrrole 7 with enone 8. 
14, 15
 Cross metathesis with methyl vinyl ketone provides enone 8, 
previously synthesized directly from  pyrrole-2-carboxaldehyde 11 (Scheme 1).
16
  
Scheme 1. Lindsley’s retrosynthetic analysis 
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 The three step sequence to enone 8, as detailed in Scheme 2, involved Grignard 15 
addition to 1-(phenylsulfonyl)-1H-pyrrole-2-carbaldehyde (11), providing secondary alcohol 12. 
Ley oxidation to ketone 13 followed by a one-pot addition, rearrangement, deoxygenation and 
elimination cascade developed by Muchowski afforded intermediate 14.
16
 Notably, application 
of Muchowski’s one-pot cascade was only pursued after preliminary disconnection pathways 
involving both sp
2
-sp
3
 Suzuki couplings and SN
2
 reactions with 2-pyrrole organometallics (Li or 
B(OH)2) failed to provide 14. Similarly, SN
2
 disconnection pathways involving organometallic 
reagents and primary bromo- or mesyl- substituted pyrroles failed.
8
 
 
Scheme 2. Synthesis of C10-C23 fragment 
 
a) 15, THF, 0 ºC to rt. b) TPAP, NMO, CH2Cl2, 4 h, rt. c) NaBH4, i-PrOH, 24 h, 82 
ºC. d) 0.5 mol % Grubbs-II (16), CH2Cl2, 12 h, 25 ºC. NMO = N-methylmorpholine-
N-oxide, TPAP = tetrapropylammonium perruthenate. 
 
Completion of the enone fragment under standard cross-metathesis conditions with 0.5 
mol % Grubbs-II (16) and methyl vinyl ketone provided 8 as a minor product in 21% yield. 
Interestingly, the major reaction pathway underwent Grubbs-II (16) catalyzed nucleophilic 
conjugate addition of 14 (at C10) with methyl vinyl ketone. Further experimentation revealed the 
reaction to be general with respect to both electron rich pyrroles and acyclic Michael acceptors.  
 7 
However, increasing catalyst loading from 0.5 to 30 mol % and reducing reaction temperature 
permitted the further isolation of cross-metathesis product 8 in 40% yield. 
8
 
Acid-mediated condensation of the resulting enone 8 with bipyrrole 7, previously 
synthesized via literature protocol, generated the acyclic Diels-Alder substrate 9. As shown in 
Scheme 3, the proposed biomimetic Diels-Alder reaction of 9 to deliver the desired spiro-fused 
aminal core (10) was unsuccessful despite the exploration of various reaction conditions.  Further 
molecular modeling studies revealed a large degree of flexibility present in the alkyl linker 
moiety, indicating an intramolecular Diels-Alder mechanism is likely energetically disfavored.
8
  
 
Scheme 3. Failed synthesis of spiro-tetrahydropyran-dihydropyrrole aminal core 10 
 
a) 7, 0.87 M HCl, MeOH than NH4OH. b) Reaction conditions = heat, microwave, 
photochemical, Lewis acid catalysis, mineral acid catalysis, solvent, and additives. 
 
Snider’s biosynthetic efforts have focused mainly on the generation of a model system 
for the unprecedented spiroiminal fragment.  The retrosynthetic analysis attempts to mimic an 
alternative biological pathway, previously suggested to involve the participation of several 
nonheme iron-dependent dioxygenases. As displayed in Scheme 4, the key disconnection results 
from simultaneous spiroiminal and tetrahydropyran ring formation from intermediate 18. 
Synthesis of intermediate 18 was believed to proceed via stepwise hydrogenolysis of the N-O 
bond followed by O-methylation of isoxazoline 19. Furthermore, the synthesis of 19 was 
envisioned to proceed through a series of addition, protection, and N-oxide cycloaddition of 
lactone 20.
9
  
 8 
Scheme 4. Snider’s retrosynthetic analysis 
 
 
To investigate this sequence, model lactone 21 which lacks the macrocyclic ring of 4 was 
selected (Scheme 5). A series of vinyl addition, secondary alcohol protection, followed by N-
oxide cycloaddition with the derivative of 1-SEM-pyrrole-2-carboxaldehyde oxime (28) resulted 
in the formation of isoxazoline 23.  Hydrogenolysis of the N-O bond over Raney nickel followed 
by methylation produced the spiroiminal precursor 24. Treatment of 24 with 2 M aqueous 
hydrochloric acid hydrolyzed the triethylsilyl ether with a net loss of methanol, forming 25 in 
35% yield, along with an inseparable 3:2 mixture of 26 and 27.
9
 
Scheme 5. Synthesis of model spiroiminals 
 
a) vinylmagnesium bromide, THF.  b) TESCl, Et3N, DMAP, THF. c) 28, 5% aqueous NaOCl, 
CH2Cl2. d) Raney Ni 2800, H2, MeOH. e) NaH, MeI, THF, 25 ºC. f) 2 M aqueous HCl, 1:3 
THF/CH3CN. TESCl = chlorotriethylsilane, DMAP = 4-(dimethylamino)pyridine. 
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1.2.2 Synthetic Strategies of Modeled Compounds 
Synthetic approaches based on the formation of model systems of the macrocyclic core and 
spiroiminal fragments of marineosins A and B (4, 5), have recently been reported by Lindsley 
and Shi.
13,12
 Shi’s retrosynthetic analysis indicated in Scheme 6, targets the spiroiminal fragment 
of marineosins A and B (4, 5). This approach relies on the late installation of the sensitive 
pyrrole ring via a Vilsmeier-Haack type reaction to afford 17. Spiroiminal formation was 
envisioned to occur through acid-catalyzed N-acyliminium ion cyclization of 30, prepared from 
commercially available reagents 31 and 32. 
13
   
 
Scheme 6. Shi’s retrosynthetic analysis of spiroiminal fragment 
 
 
A finalized synthesis of spiroaminal lactams 34 and 35 is displayed in Scheme 7. The 
route commences with DIBAL-H reduction of γ–valerolactone (31), followed by treatment of the 
resulting hemiacetal with 4-methoxy-3-pyrrolin-2-one (32) and 4N NaOH in MeOH to give 30. 
Cyclization was achieved utilizing  p-TsOH·H2O to afford 33, followed by hydrogenation to 
yield isomers 34 and 35 in 27% and 64% yield respectively.
13
   
 10 
Scheme 7. Synthesis of model spiroaminal lactam 
 
a) DIBAL-H, CH2Cl2. b) 32, 4N NaOH, MeOH, 55 ºC. c) p-
TsOH·H2O, CHCl3, 60 ºC. d) Pd/C, H2 (50 atm), MeOH, 60 ºC.  
 
 Final installation of the pyrrole ring involving a Tf2O mediated Vilsmeier-Haack type 
reaction, resulted in the formation of three spiroiminal stereoisomers (Figure 4). Unfortunately, 
the stereochemistry of both synthetic targets was unrealized. In the case of marineosin B (5), 
isomer 37 reflects the desired stereochemistry, however 36 and 38 are unnatural products.  
However, the authors contribute a degree of stability to the presence of the fused macrocyclic 
ring in the natural product, making the desired stereochemistry of marineosin A (4) more 
favorable.
13
  
 
 
Figure 4. Synthesized spiroiminal stereoisomers 
 
 Similarly, Lindsley has recently focused on the synthesis of the model spiroiminal 
structure 41 and macrocyclic fragment 40 (Figure 5). The retrosynthetic analysis hinges on the 
formation of 39, which is utilized as an intermediate en route to 40 and 41. Synthesis of key 
 11 
intermediate 39 commenced with an aldol reaction under Crimmins’ conditions to deliver Evans’ 
syn product 44, from aldehyde 42 and 43. Hydrolysis of the auxiliary followed by TIPS 
protection, hydroxyl-directed epoxidation, benzyl protection of the secondary alcohol, and PMB 
deprotection resulted in the formation of 45 in 14% yield over 5 steps.  Finally, directed opening 
of the epoxide with Red-Al, protection of the primary hydroxyl group and conversion of the 
secondary alcohol to methyl ether afforded key intermediate 39 (Scheme 8).
12
  
 
Figure 5. Lindsley’s key retrosynthetic fragments 
 
 Access to the model spiroiminal of marineosins A and B (4, 5) from intermediate 39 was 
initiated by a sequence of reductive deprotection of pivalate followed by oxidation of the 
resulting alcohol to aldehyde, Pinnick oxidation to the corresponding carboxylic acid and final 
coupling with ammonium chloride to provide amide 47.  Hydrogenolysis of the benzyl ether and 
hydrogenation of the olefin, followed by oxidation of the resulting secondary alcohol and acid 
mediated cyclization resulted in the formation of 41 (Scheme 9, part a).
12
  
 
 
 
 
 12 
Scheme 8. Synthesis of key intermediate 39 
 
a) 1. TiCl4, DIPEA, NMP, CH2Cl2; 2. 42, CH2Cl2. b) 1. LiBH4, MeOH, THF; 2. TIPSCl, ImH, CH2Cl2. c) 
VO(acac)2, TBHP, CH2Cl2.  d) 1. BnBr, NaH, TBAI, THF; 2. DDQ, CH2Cl2, pH 7 phosphate buffer. e) Red-Al, 
THF. f) 1. PivCl, pyr, CH2Cl2; 2. Me3OBF4, CH2Cl2.  
 
 A synthesis of the macrocyclic fragment 40 commences with a sequence of TIPS 
deprotection, oxidation, vinyl Grignard addition and second oxidation to afford α, β–unsaturated 
ketone 48 (Scheme 9, part b).  Stetter reaction of 48 with 6-heptenal afforded the RCM substrate 
49. A final ring closing metathesis of 49, followed by microwave assisted pyrrole construction 
afforded target macrocycle 40 in 5.1% overall yield from (S)-propylene oxide.
12
  
 
 13 
Scheme 9. Synthesis of model spiroiminal and macrocyclic fragments 
 
Part A. a) DIBAL-H, CH2Cl2. b) SO3-pyr, Et3N, DMSO. c) 1. NaO2Cl, NaH2PO4, 2-methyl-2-butene; 2. EDC, 
HOBt, NH4Cl, DMF. d) 1. Pd/C, H2, EtOAc; 2. TPAP, NMO, CH2Cl2. e) 0.01M HCl, MeOH. Part B. a) 
BF3·OEt3, CH2Cl2. b) SO3-pyr, Et3N, DMSO. c) 1. vinylmagnesium bromide, THF; 2. Dess-Martin periodinane, 
CH2Cl2. d) 6-Heptenal, Et3N, thiazolium hydrochloride, 1, 4-dioxane. e) Grubbs I catalyst (30 mol %), CH2Cl2 
(0.0005 M). f) NH4OAc, MeOH, microwave irradiation.  
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2.0   EFFORTS DIRECTED TOWARDS THE MACROCYCLIC CORE OF 
MARINEOSIN A 
2.1 LIMITATIONS OF PREVIOUS STRATEGIES 
Previous syntheses performed by Lindsley and others, which target the spiroaminal and 
macrocyclic ring systems of marineosins A and B, have focused on the development of model 
systems. Additionally, biomimetic studies initiated by Fenical and Snider, have failed to generate 
the tetrahydropyran core and spiroiminal fragment of marineosins A and B. However, the 
cytotoxic activities and the unique structural aspects of marineosin A and B, continue to generate 
interest in these marine derived natural products. Therefore, a direct and efficient route towards 
the total synthesis of marineosins A and B is needed. 
2.2 EFFORTS UTILIZING ENOLATE ALLYLIC ALKYLATION  
2.2.1  Retrosynthetic Analysis 
Our strategy features an intramolecular ruthenium-catalyzed enolate allylic alkylation of 
disubstituted allylic acetate 54, resulting in the formation of product 53 containing the core of 
marineosin A (Scheme 10). The spiroiminal fragment of 4 was envisioned to be installed in two 
 15 
subsequent steps. Addition of α-metalated pyrrole into the impending nitrile, followed by attack 
at C8 by the resulting imine provides the first major disconnection. Ozonolysis of substrate 51, 
results in hemiketal formation and construction of the pyran ring.  We further planned a series 
global deprotection, oxidation, and asymmetric addition of cyanomethylzinc bromide to afford 
product 51. With the major framework of the macrocycle to be constructed via an enolate allylic 
alkylation reaction of disubstituted allylic acetate 54, we initially sought to generate model 
substrate 63 which lacked the C14-C19 fragment (Scheme 11). 
 
Scheme 10. Proposed retrosynthetic analyses of marineosin A 
 
2.2.2 Ruthenium-Catalyzed Enolate Allylic Alkylation 
An alternative route towards Claisen products of type 59 has previously been developed in our 
group, utilizing easily prepared pyrrole silyl enol ether 55, and allylic acetate 56.
17
 This 
ruthenium-catalyzed enolate allylic alkylation methodology provides similar C-C bond 
connections traditionally obtained from Claisen reactions, while maintaining high diastereo- and 
 16 
enantioselectivity (Scheme 11). A mechanism for the transformation of 56 to 59 is believed to 
proceed via oxidative addition into the C-O σ-bond of allyl acetate 56, followed by nucleophilic 
addition of silyl enol ether 57 to the resulting Ru-bound 58. However, the extension of this 
methodology to disubstituted allylic acetates of type 61 as the pro-electrophile, and the 
application of this methodology to natural product synthesis is previously unexplored. An 
analogous mechanism leading to the formation of 63, involves the oxidative addition of 
ruthenium into a single C-O σ-bond of allylic diacetate 61.  Nucleophilic addition of silyl enol 
ether 57 into the newly formed Ru-bound intermediate 62 is expected to result in the formation 
of 63 (Scheme 11).  
Scheme 11. Ruthenium-catalyzed enolate alkylation of 56 and 61 
 
 
 
To investigate the applicability of the ruthenium-catalyzed enolate allylic alkylation 
methodology towards the synthesis of the core of marineosin A, we initially focused our efforts 
on the preparation of allylic diacetate 65, which we planned to utilize in the reaction with pyrrole 
silyl enol ether 55 (Scheme 12). We chose to omit the C14-C19 linker, which would later 
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constitute the macrocyclic core during our initial studies, in order to probe the reactivity of the 
substrate. Completion of the synthesis of model substrate 68, involves global deprotection of 66, 
and subsequent oxidation of the resulting primary alcohol function of 67 (Scheme 12). Since the 
electronic properties of protecting groups are known to modulate pyrrole reactivity, we planned 
on implicating both benzyl and TIPS groups to test this effect. Additionally, both benzyl and 
TIPS groups are stable towards the planned deprotection and alcohol oxidation conditions 
(Scheme 12).  
To begin our studies into the reactivity of allylic diacetates, we synthesized cinnamyl 
diacetate (76) as a precursor to the pyrrole derivative. Knoevenagel condensation of 
benzaldehyde (73) with diethylmalonate followed by DIBAL reduction and acylation afforded 
the pro-electrophile 76 in 51% yield over 3 steps (Scheme 13). Exposing cinnamyl diacetate (76) 
and pyrrole silyl enol ether 85 to 5 mol % of Ru(II) complex generated in situ through the 
reaction of [Cp*Ru(CH3CN)]PF6 with ligand 90, in the presence of B(OPhpNO2)3 gave no 
reaction after 24 h.
18
 Additional reactions performed at 50 °C or using [CpRu(CH3CN)3]PF6 as 
an alternative catalyst gave no reaction after 48 h (eq 1).  
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Scheme 12. Forward synthetic route to model substrate 68 
 
 
The inconclusive results obtained from our model system encouraged us to seek 
alternative substrates, to further investigate the application of this methodology. We next sought 
to directly synthesize diacetates 80 and 84, which lack the C14-C19 linker (Scheme 13). 
Knoevenagel condensation of differentially protected pyrrole 2-carboxaldehydes 77 and 81 
resulted in the formation of 78 and 82 in 95% and 98% yield. However, the reduction of 78 and 
82 with DIBAL proceeded to 1, 4-reduction of the double bond as the dominant pathway. This 
may be attributed to the formation of a stabilized aluminum intermediate, which redirects 
hydride delivery. The competing 1, 2-reduction of 78 and 82 provided the desired products 79 
and 83 in 6% and 30% yield, in 10 minutes at -78 °C.  Acylation of the resulting diols delivered 
diacetates 80 and 84 in moderate yields of 80% and 88% (Scheme 13). 
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Scheme 13. Synthesis of diacetates 80 and 84 
 
a) diethyl malonate, piperdine, DMAP, 50 °C. b) DIBAL, CH2Cl2, -78 °C, 10 min. c) acetyl chloride, pyridine, THF, 
0 °C. d) DMAP = 4-dimethylaminopyridine, DIBAL = diisobutylaluminium hydride. 
 
 
 To investigate the alkylation of N-protected pyrrole derivatives with silyl enol ethers, we 
next examined the reactions of diacetates 80 and 84. Exposing N-benzylpyrrole allylic diacetate 
80 and pyrrole silyl enol ether 85 to 5 mol % of Ru(II) complex generated in situ from 
[Cp*Ru(CH3CN)]PF6 and ligand 90, in the presence of B(OPhpNO2)3 resulted in <10% 
conversion to the linear product as determined by 
1
H NMR (eq 2). Alternatively, exposing N-
TIPS pyrrole allylic diacetate 84 to Ru(II)-catalytic conditions resulted in the complete 
conversion of 84 to bicyclic caprolactam 89 in 24 h (eq 3). An X-ray crystal structure of 89 is 
displayed in Figure 6. 
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Figure 6. X-ray crystal structure of 89 
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 The mechanism of 89 formation is believed to involve oxidative addition of Ru(II) across 
the allylic acetate C-O σ-bond, resulting in the formation of a reactive allylic intermediate 
(Scheme 14). With simple substrates enolate addition typically favors the more highly 
substituted center, resulting in the bias formation of branched Claisen-type products. However, a 
reversal in enolate preference may be explained by a more sterically hindered allylic 
intermediate, leading to the exclusive formation of linear product 91. Oxidative addition of 
Ru(II) across the second allylic acetate C-O σ-bond of 91, results in the formation of allylic 
intermediate 92. Intramolecular attack by pyrrole on the reactive intermediate (92) and 
subsequent rearomatization results in the formation of the observed product (89) (Scheme 14).  
 
Scheme 14. Possible mechanism for the formation of 89 
 
 
 In conclusion, the extension of ruthenium-catalyzed enolate allylic alkylation 
methodology to disubstituted allylic acetates is a nonproductive route towards the synthesis of 
marineosin A (4). However, based on these studies a novel route to bicyclic caprolactam 
structures has been identified.  
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2.3 EFFORTS UTILIZING AZAFULVENE DIMER METATHESIS  
2.3.1 Retrosynthetic Analysis 
With the primary objective of developing an operative path towards the selective generation of 
marineosin A (4), we next developed an alternative retrosynthetic analysis implementing an exo-
selective hetero Diels-Alder reaction. Our modified retrosynthetic analysis commences with the 
disconnection of the spiroiminal fragment via stereoselective C8-H insertion of an acyl nitrene or 
nitrenoid intermediate, resulting from the breakdown of acyl azide 93.  A sequence of t-butyl 
ester hydrolysis, acid chloride conversion, followed by azide addition provides compound 93. 
The t-butyl ester 94 was envisioned to be installed though metal hydride-mediated reduction of 
the C8 α–alkoxy ester, followed by Mukaiyama aldol addition into the corresponding aldehyde. 
Hydrogenation of the C21-C22 double bond of 96, and subsequent methyl transfer provides 95. An 
exo-selective hetero Diels-Alder reaction with ethyl glyoxylate (98) generates tetrasubstituted 
pyran 96 (Scheme 15).  
 
Scheme 15. Proposed retrosynthetic analyses of marineosin A 
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2.3.2 Azafulvene Dimer Derived Metathesis 
To generate the key Diels-Alder precursor 97, we chose to initiate our study with a domino ring-
closing /cross-metathesis reaction of enyne 99 in the presence of vinyl acetate. Construction of 
99 was expected to proceed through a short sequence of nitrogen protection, and subsequent 
olefination of pyrrole-2-carboxaldehyde 101. Alkylation of azafulvene dimer 103 with 
iodoalkane 104, and hydrolysis of the resulting intermediate (102) could provide 101 in a single 
step.
19
 Protecting the resulting aldehyde was especially important, since the basicity and 
nucleophilicity of nitrogen atoms deactivate the catalyst through coordination with the metal 
center. Notably, this process is advantageous due to the possible formation of a variety of 5-
substituted pyrrole-2-carboxaldehydes (Scheme 16).  
Scheme 16. Retrosynthetic analysis using azafulvene dimer 
 
 
In order to investigate our planned ring-closing metathesis we first examined the 
synthesis of aldehyde precursor 101. The three step synthesis of iodoalkyne 108 initiated with 
the triple bond isomerization of alkyne 105, by a zipper reaction to afford terminal alkyne 106. 
Trimethylsilyl protection of the terminal alkyne and successive halogenation afforded 108 in 
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80% yield over 3 steps (Scheme 17). To prevent the formation of the corresponding lithium 
acetylide during the course of the alkylation reaction, terminal alkyne protection was required.  
Employing 108 as the electrophile, alkylation of azafulvene dimer 103 with n-BuLi in THF at     
-78 °C resulted in the formation of 109 (32%). While attempts to install tosyl or t-Boc nitrogen 
protecting groups were unsuccessful on this substrate, benzyl protection proceeded to the desired 
substrate 111 in 60% yield. These results indicate steric hindrance, as well as, the electron 
withdrawing effect of the adjacent aldehyde may impact pyrrole protection. Olefination of the 
aldehyde function, followed by trimethylsilyl deprotection of the terminal alkyne proceeded to 
yield the metathesis substrate 114 in 74% yield over two steps (Scheme 18).  
 
Scheme 17. Optimized synthesis of iodoalkyne 108 
 
a) ethylene diamine, NaH, 60 °C. b) n-BuLi, TMSCl, -78 °C. c) PPh3, ImH, I2, rt. TMS = trimethylsilyl, ImH = 
imidazole.  
 
We next sought to investigate the tandem ring-closing/cross-metathesis reaction which 
would afford diene 115. However, in the presence of 10 mol % Grubbs-II catalyst (16) and vinyl 
acetate (117) (0.01M CH2Cl2, rt) no anticipated ring-closed product was observed (Table 1, entry 
1). Substituting Hoyveda-Grubbs-II catalyst (118) in place of Grubbs-II (16) resulted in the 
incomplete conversion of 114 to disubstituted derivative 116 (entry 3). Similar results were 
obtained at elevated temperatures (0.01M toluene, 100 °C), resulting in the formation of no ring-
closed products (entries 2 and 4).  However, derivative 116 was formed in 32% yield at elevated 
temperature utilizing Hoyveda-Grubbs-II catalyst (118), indicating that cross-metathesis of the 
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terminal alkyne with vinyl acetate (117) proceeded as the dominant pathway.  Additionally, 
reactions performed in the presence of ethylene (1 atm) resulted in the complete decomposition 
of substrate 114. This result was in accordance with previous reports in which metatheses of 2-
vinyl aromatic heterocycles do not proceed at an appreciable rate.
20
 In particular, 2-vinyl 
pyrroles may display diminished reactivity due to the possible formation of a charged resonance 
intermediate, impeding the formation of an electron rich carbon-ruthenium bond and enabling 
the competing alkyne metathesis.  
Scheme 18. Synthesis of enyne substrate 114  
 
a) n-BuLi than NaHCO3. b) NaH, TsCl; NaH BnBr; DMAP, Boc2O. c) 
CH3PPh3Br, KHMDS. d) K2CO3, MeOH. Ts = tosyl, DMAP = 4-
dimethylaminopyridine, Boc = t-butoxycarbonyl, KHMDS = Potassium 
hexamethyldisilazide.  
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Table 1. Enyne metathesis approach to marineosin macrocycle  
 
a 
Reaction conditions: 4 equivalents of vinyl acetate (117).
 b 
Reaction conditions: ethylene 
(1 atm).
c
 0.01M solvent. 
d 
Determined by crude 
1
H NMR spectra. 
 
 To promote intramolecular enyne metathesis, and favor the formation of the macrocyclic 
core, we next employed a relay ring-closing metathesis strategy for directing metal activation.  
This relay strategy,  initially developed by Hoye and coworkers, has previously been utilized to 
direct metal movement to poorly reactive alkenes.
21
 To generate relay substrate 122, we initiated 
our synthesis with alkyne deprotection, followed by a Horner–Wadsworth–Emmons reaction to 
afford E-alkene 120 (Scheme 19).  Diisobutylaluminium hydride-mediated reduction and O-
allylation afforded the desired relay substrate 122.  As displayed in Table 2, ring-closing 
conditions utilizing 15 mol % Grubbs-II (16) at 60 ºC over 24 h in 1,2-dichloroethane (DCE) 
produced none of the desired product 115 (entry 1). Similarly, the addition of 1-4 equivalents of 
vinyl acetate (117) yielded only starting material (entries 3 and 4). These results may be 
attributed to the formation of unstable 1,3-diene intermediates resulting in alkyne 
polymerization, in the absence of vinyl acetate (117). In an attempt to bypass 1,3-diene 
formation, 1,4-benzoquinone (BQ) was additionally investigated as an additive for the desired 
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metathesis reaction based on the previous success of Diver and coworkers.
22
 Unfortunately, 7.5 
mol % 16, in the presence of 10 mol % BQ produced no desirable results (Table 2, entry 2).  
 
Scheme 19. Synthesis of relay-ring closing substrate 122  
 
a) K2CO3, MeOH. b)  triethyl phosphonoacetate, KOH, THF. c) DIBAL-H, 
CH2Cl2. d) allyl bromide, NaH, THF. DIBAL = diisobutylaluminium hydride. 
Table 2. Relay-ring closing metathesis approach 
 
a
 Catalyst loading: 15 mol %. 
b 
Catalyst loading: 7.5 mol %. 
c 
1 
equivalent vinyl acetate (117). 
d
 4 equivalents vinyl acetate (117). 
 
 
 Alternatively, we sought to synthesize 129, which would constitute the macrocyclic core 
of diene 115, with the goal of eliminating competing pathways associated with initiation at the 
alkyne. Based on the approach implemented by Donohoe for the completion of the furan core of 
cembranolide, we next investigated the utility of olefin metathesis for macrocycle formation 
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(Scheme 20).
23
 Cross-coupling of 1-bromo-6-chlorohexane (123) with allylmagnesium bromide 
in the presence of CuCl afforded 124 in 70% yield. This species underwent chloride 
displacement under Finkelstein conditions to provide 125 in 93% yield (Scheme 20).
24
 
Accordingly, alkylation of azafulvene dimer 103 with 125, followed by hydrolysis of the 
resulting alkylated species afforded aldehyde 126 in 51% yield. Nitrogen protection of the 
pyrrole 126, followed by Wittig olefination of the aldehyde function provided the olefin 
metathesis substrate 128 in 38% yield over two steps. However, the attempted intramolecular 
olefin metathesis of 128 in the presence of either Grubbs-II (16) or Hoyveda-Grubbs (118) 
catalysts produced no detectable ring-closing derivative and recovery of the substrate (128). 
Furthermore, prolonged reaction times and elevated reaction temperatures were unable to effect 
the desired transformation.  Presumably, entropic factors which limit the probability of end-to-
end encounters in larger ring systems are responsible for the observed results.  In addition, a 
higher activation barrier due to increased ring stain is evident in larger size rings.
25
  
 
Scheme 20. Ring-closing metathesis approach  
 
a) allylmagnesium bromide, CuCl, Et2O, -78 °C. b) NaI, acetone, 60 °C. c) 103, n-BuLi 
than NaHCO3. d) NaH, BnBr. e) CH3PPh3Br, KHMDS. f) 10 mol % 16 or 118, ethylene 
(1 atm), 0.01M CH2Cl2, rt, 24 h. g) 10 mol % 16 or 118, ethylene (1 atm), 0.01M toluene, 
100 °C, 48 h. HMDS = hexamethyldisilazane.  
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2.4 CONCLUSIONS 
We have presented two dissimilar approaches with the primary objective of developing an 
operative path towards the generation of marineosin A. The extension of an enolate allylic 
alkylation approach to disubstituted allylic acetates resulted in the formation of bicyclic 
caprolactam structure 89. However, no operative route towards the synthesis of marineosin A 
was established. Primarily due to the diminished reactivity of N-protected pyrrole derivatives 
towards silyl enol ether 85, in the presence of catalytic amounts of ruthenium (II). In addition, an 
azafulvene dimer metathesis strategy was investigated as a potential route towards the 
macrocyclic core of marineosin A. However, we were unable to affect the desired ring-closing 
metathesis, presumably due to the diminished reactivity of 2-vinyl pyrrole derivatives, as well as, 
entropic factors which limit the reactivity of larger ring systems.   
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3.0  INTRODUCTION 
3.1 DIVERSITY-ORIENTED SYNTHESIS OF NATURAL PRODUCT-LIKE 
STRUCTURES 
Diversity-oriented synthesis (DOS) involves the deliberate, simultaneous and efficient synthesis 
of multiple targets that are not only diverse in the appendages they display, but also in their 
molecular architectures.
26
 In contrast to target-oriented synthesis and combinatorial chemistry 
(focused library synthesis), diversity-oriented syntheses are not aimed at one particular target 
(Figure 7).  In these approaches retro-synthetic analysis is used to theoretically deconstruct 
complex target molecules into simple starting materials.  In DOS, a “forward synthetic” strategy 
must be constructed to facilitate the transformation of simple starting materials into an array of 
complex and diverse products.
27
  
 
 
 
Figure 7. Sources of skeletally diverse small molecules 
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This process first described in the pioneering work of Schreiber, aims  to synthesize 
collections of molecules that represent the variety of charges, polarities, bonding interactions and 
architectures that can potentially be recognized by nature’s biomolecules.26 Over the last few 
years, the potential for DOS has been exemplified by the synthesis of discrete skeletons with 
unique motifs. While several strategies have focused on structural motifs such as benzopyran, -
amino alcohol, allenoate and indole cores for the synthesis of alkaloid-like skeletons and ring 
systems, the diversity-oriented strategies of pyrrolidines remains relatively unexplored.
28,29
 
Pyrrolidines are an important class of heterocycles that have been found in numerous 
natural products and have served as useful molecular scaffolds in medicinal structures. For 
example, in cancer research small molecule MDM2 inhibitors based on the spirocyclic oxindole-
pyrrolidine core of natural alkaloids such as spirotryprostatin A and alstonisine have showed 
good selectivity between cancer and normal cells with wild-type p53.
30
 Neuroprotective agent 
kaitocephalin
31
, hepatitis C virus RNA polymerase small molecule inhibitors
32
, the synthetic 
influenza drug A-192558
33
 and the antitumor antibiotic bioxalomycin 134 all are examples in 
which the pyrrolidine ring is an important structural motif. Accordingly, the diversity-oriented 
synthesis of natural product-like libraries in which pyrrolidine scaffolds provide a core for the 
development of structurally complex, stereochemically rich and densely functionalized 
substructures are needed. 
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3.2 PREVIOUS APPLICATIONS OF 1, 3-CYCLOADDITION REACTIONS FOR 
REGIO- AND STEREO-SPECIFIC FORMATION OF PYRROLIDINES 
The [3+2] cycloaddition reaction of azomethine ylides with electron poor dipolarophiles is a 
powerful and concise method for the synthesis of highly substituted five-membered ring 
heterocycles.
35
 Specifically, the dipolar cycloaddition of and azomethine ylide and an electro-
deficient olefin is a valuable transformation because it creates two carbon-carbon bonds and four 
potential stereocenters in a single step. The biological importance of pyrrolidines has encouraged 
the advancement of diastereo- and enantioselective [3 +2] cycloadditions of azomethine ylides, 
and several routes to these 1, 3-dipoles have been developed.
36
 Among the different versions of 
this reaction, the most practical approach has been the interaction of stabilized N-metalated 
azomethine ylides 132 with electron deficient alkenes 133 (Scheme 21).
36a, 37
   
 
Scheme 21. [3+2] cycloaddition of N-metalated azomethine ylide with electron deficient alkenes 
 
 
The enantioselective version of this transformation utilizing chiral based ligands was first 
investigated in 1991 by Grigg.
38
 Using a stoichiometric amount of Co(II) and the chiral 
ephedrine ligand 138, the reaction of azomethine ylide 135 with methyl acrylate (136) primarily 
resulted in a single enantiomer of pyrrolidine 137 (eq 4). While reaction time and enantiomeric 
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excess of the product remained unchanged in a variety of solvents, the use of cobalt chloride 
demonstrated a profound effect on both values. The choice of a molar equivalent of CoCl2 and 
the chiral ephedrine ligand 138 gave the highest yields (45-84%) with an appreciable 
enantiomeric enrichment of 96%. However, a substantial amount of imine hydrolysis and 
dimerization was observed in these reactions.
36a, 38
  
 
 
 The observed facial selectivity of these reactions is rationalized by using transition state 
142 (Figure 8). Due to the cis-conformation of the methyl and phenyl groups on the ligand, 
addition occurs only at the less hindered face of the ylide.
38
 Grigg has additionally reported 
utilizing AgOTf and a chiral bisphosphine ligand on identical substrates, however detailed 
reaction conditions such as catalyst loading and substrate scope were not reported.
39
 
 
Figure 8. Proposed transition state of Co (II)/ephedrine ligand 
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Catalytic variants of Griggs’ stoichiometric cycloadditions of N-metalated azomethine 
ylides have more recently been demonstrated by Jørgensen and Zhang.
35, 40
  In 2002, Jørgensen 
investigated the reactions of  N-benzylidene- and N-(2-naphthylmethylidene) glycinates 143 and 
139, with methyl acrylate (136) in the presence of catalytic Cu(OTf)2 and Zn(OTf)2 and chiral 
bisoxazoline ligands. Optimized conditions for the formation of pyrrolidines 145 and 146 were 
obtained with catalytic Zn(OTf)2 and chiral bisoxazoline ligand (S)-t-Bu-Box-ligand (144) (eq 5). 
Reactions with a series of imines of glycine methyl ester and various electron deficient alkenes 
catalyzed by Jørgensen’s system have demonstrated a variety of yields (12% to > 95%) and 
enantiomeric enrichments (<5% to 94%) (Figure 9).
35
 
 
 
 
Work completed by Zhang further examined the cycloadditions of azomethine ylides 
utilizing catalytic Ag(I) in conjunction with various chiral phosphine ligands.  However, initial 
investigations of this catalyst system with benzylidene glycinate 143 and dimethylmalenate 
(147), failed to promote substantial diastereo- or enantioselectivies and  resulted in poor 
conversions.
40
 Addition of the Trost modular ligand 148,
41
 previously utilized in asymmetric 
allylic alkylations resulted in a significant improvement in reactivity and enantioselectivity (94% 
yield and 76% ee).  An additional increase in selectivity was also observed upon replacement of 
the phenyl groups with 3,5-dimethylphenyl (86% ee) (eq 6).
40
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Overall, reactions employing imines of glycine methyl ester with various olefins 
catalyzed by Zhang’s AgOAc/xylyl-FAP system demonstrated higher yields (73-98%) and 
enantiomeric enrichment (70% to 97% ee) then previously reported by Jørgensen’s system.  
Representative members resulting from the [3 + 2] cycloaddition of azomethine ylides with 
typically used olefins is shown in Figure 9.  In all cases only the endo products were isolated.  
Alkyl imino esters were found to be significantly less reactive under the same conditions with 
lower yields and ee (82% yield over 48 h, 70-81% ee).
40
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Figure 9. Application of Jørgensen’s Zn(OTf)2/t-BuBOX
a
  and Zhang’s AgOAc/xylyl-FAPb systems to 
development of pyrrolidine libraries 
3.3 SYNTHESIS OF FUSED PYRROLIDINE-HYBRID LIBRARIES 
Based upon the previous chiral catalyst studies developed by both Zhang and Jørgensen, 
Schreiber has applied 1,3-dipolar cycloaddition reactions to the synthesis of fused pyrrolidine 
libraries.  Focusing on silver (I) acetate reactions with chiral phosphine ligands previously 
engaged in Zhang’s work, Schreiber has examined six additional commercially available chiral 
phosphines. The reaction which was initially explored with methyl  
N-benyzlidene glycinate 143 and t-butyl acrylate is displayed in Table 3, entry 1. Unexpectedly, 
of the commercially available ligands examined the P, N ligand (S)-QUINAP (159) displayed the 
best levels of both diastereo- and enantioselectivity.
42
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Table 3. Exploration of dipolarophile reactivity with Schreiber’s catalyst 
 
a
 Catalyst loading: 3 mol%. 
b
 Catalyst loading: 10 mol%. 
c 
Combined yield endo/exo 
products. 
d 
Enantioselectivity exo product. 
e
 Determined by crude 
1
H NMR spectra. 
 
To further expand the scope of the reaction, the nature of the aromatic group was also 
explored. Exchanging the aromatic substituent on -imino ester 143, with 4-methoxyphenyl,  
4-cyanophenyl, 2-tolyl, and 2-napthyl groups under the same conditions similarly demonstrated 
high levels of diastereoselectivity (>20:1) and enantioselectivity (94-96% ee) regardless of the 
electronic properties of the rings. However, the sterically hindered 2-tolyl gave lower 
enantioselectivity (95% yield, 89% ee). Analysis of the reactivity of the Schreiber’s catalyst 
system with different electron-deficient olefins is shown in Table 3. The proposed transition state 
161 is thought to derive selectivity by sterically hindering one face of the 1, 3-dipole limiting the 
approach of the incoming dienophile (Figure 10).
42
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Figure 10. Proposed transition state of Ag(I)/QUINAP catalyst 
 
Schreiber’s work is the first example of a catalytic asymmetric cycloaddition of 
azomethine ylides to be featured in the parallel synthesis of a fused pyrrolidine scaffolds. The 
diversity-oriented synthesis which builds upon these scaffolds has resulted in the formation of 
bridged-piperdine/fused-pyrrolidine and spirocycle-oxindole/fused-pyrrolidine hybrid libraries.
43
 
A key feature of Schreiber’s new catalyst system for diversity-oriented synthesis of pyrrolidine 
hybrid-libraries is the extension of this reaction to 500-600 μm polystyrene “macrobeads”. As 
displayed in Scheme 22, pyrrolidine scaffolds could be initially loaded onto alkylsilyl-
derivatized macrobeads. Coupling with various protected amino acids (glycine, leucine, 
phenylalanine, and proline) provided after deprotection the 24 member sublibrary (163). The 
resulting pyrrolidine scaffolds were then released and coupled to bridged piperdine (162) 
structures and spirocyclic-oxindole (165) structures or inversely coupled then released to yield 
the final small molecule hybrids.  In each case, final sublibrary coupling involved 
PyBOP/DMAP-promoted esterification and HF-pyridine mediated release of the surrogate 
bead.
43,44,45
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Scheme 22. Synthesis of fused-pyrrolidine hybrid libraries 
 
a)1. PyBOP, DMAP, CH2Cl2, 23 ºC, 16h; 2. HF-py, THF, 23 ºC, 2h, then TMSOEt. b) 165, HF-
py, THF, 23 ºC, 2h, then TMSOEt. DMAP = 4-dimethylaminopyridine, py = pyridine, PyBOP = 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, TMS = trimethylsilyl. 
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4.0  DEVELOPMENT OF PYRROLIDINE SCAFFOLDS FOR DIVERSITY-
ORIENTED SYNTHESIS BY CLAISEN REARRANGEMENT OF ALLYL VINYL 
ETHERS 
4.1 LIMITATIONS OF PREVIOUS STRATEGIES 
Diversity-oriented synthesis is an emerging field that seeks to enrich chemical space by the 
development of divergent pathways towards new pharmaceutically active compounds. Previous 
methodologies developed by Grigg, Zhang, and Schreiber have resulted in the formation of 
hybrid-pyrrolidine libraries. However, the electronic requirements inherent within dipolar 
cycloaddition reactions have restricted the substrate scope available via this strategy. Moreover, 
the compounds derived from this approach have yet to display any biological activities. 
Therefore, novel pyrrolidine scaffolds which build structural complexity from simple and similar 
compounds are needed to synthesize diverse libraries of natural product- and drug-like 
molecules. 
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4.2 RETROSYNTHETIC ANALYSIS OF FUNCTIONALIZED PYRROLIDINE 
SCAFFOLDS 
In the past few years, our laboratory has demonstrated the value of Ir(I)-based catalyst systems 
for the chemo- and stereoselective isomerization of bis(allyl) ether substrates.
46
 Additionally, the 
enantio- and diastereoselective Ru(II)-catalyzed Claisen rearrangement of unactivated allyl vinyl 
ethers has also been demonstrated.
47
 To validate the potential applicability of these 
methodologies to the diversity-oriented synthesis of drug-like compounds, we sought to develop 
a route to functionalized pyrrolidine scaffolds. Our retrosynthetic analysis commences with the 
reductive deprotection of β-azido amine 168, resulting in the formation of diamine 167.48  
Nucleophillic ring opening by azide at C5 or C4 of 169 results in the formation of both desired 
kinetic (168) and thermodynamic (170) products.
49,50  
The predominant process of nucleophilic 
displacement of iodine, is next expected to proceed through a SNi mechanism to generate 
aziridinium ion 169.
  
Preferential 5-exo-cyclization of 172 generates the anticipated β-iodo amine 
171.   Lastly, reductive amination of γ,δ- unsaturated aldehyde 173 will afford 172 (Scheme 23).   
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Scheme 23. Retrosynthetic analysis of racemic pyrrolidine scaffolds 
 
  
4.3 SYNTHESIS OF A GENERAL PYRROLIDINE SCAFFOLD FOR 
DIVERSIFICATION 
4.3.1 Formation of Claisen Products from Simple Allyl Vinyl Ethers 
Since its discovery in 1912 by Ludwig Claisen, the [3, 3] sigmatropic rearrangement of allyl 
vinyl ethers (174) to produce γ,δ-unsaturated carbonyl compounds (176) has been highly utilized 
in synthetic transformations.
51
  The rearrangement which proceeds through a chair-like transition 
state (175) to provide racemic syn-diastereomer 177, results in the generation of a new carbon-
carbon bond and two adjacent stereocenters (Figure 11).
52
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Figure 11. Thermal Claisen rearrangement of general allyl vinyl ether (174) 
 
Based upon the success of Ir(I)-based catalyst systems developed in our laboratory, we 
initially synthesized aldehyde 181 as a model compound en route to pyrrolidine scaffolds 
(Scheme 24). Williamson ether synthesis of cinnamyl alcohol (178) with allyl bromide, followed 
by iridium catalyzed isomerization of the terminal double bond afforded allyl vinyl ether 180 in 
88% yield over two steps. 
46
 Claisen rearrangement under thermal conditions of 180 afforded 
γ,δ-unsaturated aldehyde 181 in 93% yield (Scheme 24).   
Scheme 24. Synthesis of γ,δ-unsaturated aldehyde 
 
 
a) allyl bromide, NaH, THF. b) [Ir(COE)2Cl]2, PCy3, NaBPh4, CH2Cl2/acetone. c) 80 ºC, 
toluene. COE = cyclooctene 
4.3.2 Formation of Pyrrolidines from Claisen Products 
To validate our synthesis design, we initiated our investigation with the generation of amides 182 
and 183, along with, amines 184 and 185 (Scheme 25). Pinnick oxidation followed by treatment 
of the resulting γ, δ-carboxylic acid derivative with ammonium hydroxide and benzylamine, 
afforded primary and secondary amides 182 and 183 in 88% and 90% yield, respectively.
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 The 
secondary amine 184 was synthesized in 67% yield via reductive amination with triethylsilane 
and benzylcarbamate. Similarly, treatment of 181 with sodium triacetoxyborohydride, and 
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benzylamine afforded secondary amine 185 73% yield (Scheme 25).
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 Having successfully 
established routes to the syntheses of 182 to 185, we next sought to probe the reactivity of these 
compounds towards various electrophilic sources of iodine to complete the desired cyclization.   
 
Scheme 25. Synthesis of γ,δ-unsaturated amides and amines  
 
a) NaClO2, NaH2PO4, 2-methyl-2-butene, t-BuOH, H2O then oxalyl 
chloride. b) NH4OH (aq). c) benzylamine, CH2Cl2. d) benzyl carbamate, 
TES, TFA, MeCN.  e) benzylamine, NaHB(OAc)3, AcOH, CH2Cl2. TES = 
triethylsilane, TFA = trifluoroacetic acid. 
 
Proceeding with our planned synthesis we subjected amines 182-185 to various 
electrophilic sources of iodine, to affect the desired cyclization reaction. The use of 3 equivalents 
of elemental iodine, in combination with NaHCO3 and K2CO3 provided β-iodo amines 186-189 
in 34-51% (Table 4, entries 1-5). Alternatively, utilizing 1.1 equivalents of NIS, amines 185 and 
184, selectively afforded 5-exo-products 189 and 188 in 70% and 64% yield respectively (entries 
6 and 7). However, N-benzyl amine 185 displayed a shorter reaction time, with complete 
conversion in 20 minutes. In contrast N-carboxylbenzyl amine 184 reached completion only after 
2 h. The diminished yields and elongated reaction time of 184 may be explained by increased 
steric volume or diminished nucleophilicity of the nitrogen atom.  
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Table 4. Cyclization conditions with various electrophilic iodine sources 
 
a
 Reaction performed in the dark. 
b
 Reaction performed in the presence of ambient 
light. 
c
 3 equivalents of I2; 1.1 equivalents of NIS were utilized. 
d
 3 equivalents of base.
 
e 
Isolated yields. NIS = N-iodosuccinimide. 
  
 To decipher any effect of light on the cyclization reaction, identical reactions employing 
1.1 equivalents of NIS and N-benzyl amine 184 or N-carboxybenzyl amine 185 were monitored 
under ambient light. As demonstrated in Table 4, minimal improvements in isolated yields were 
observed for both substrates 184 and 185. These results led us to conclude, that the presence of 
light was not a decisive factor in the successful cyclization of 184 or 185. However, having 
obtained complete conversion of 185 to 189 within 20 min, along with higher isolated yields in 
comparison to the conversion of 184 to 188, we decided to employ N-benzyl amine 185 for 
further methodology development.  
 A plausible mechanism for the formation of pyrrolidine 189, involves the reversible 
formation of iodonium ion 190 upon reaction of 185 with an electrophilic source of iodine 
(Scheme 26). Intramolecular ring-opening by nitrogen at C4 of 190, provides 5-exo-cyclization 
product 189. Furthermore, transition state 191 which allows the iodonium ion, phenyl, and 
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methyl groups to occupy pseudoequatorial positions around the developing pyrrolidine ring 
provides the most stable conformation of 189.  
 
Scheme 26. Proposed mechanism of iodoamination of 185 
 
 
 At this stage, we sought to convert β-iodo amine 189 to the desired β-azido amine 192 
which, through reductive deprotection, would be converted to the desired diamine scaffold.  To 
accomplish this, we planned to generate both pyrrolidine (192) and piperdine (193) products via 
an aziridinium intermediate 195 (Scheme 27).  The existence of 195 would be expected to arise, 
from the intramolecular substitution of primary iodide by the pyrrolidine nitrogen of 189. 
Subsequent ring-opening by the azide nucleophile at either C4 or C5, would result in the 
formation of 192 and 193. Reacting 189 with sodium azide (1.5 equivalents, DMF, 50 °C) led to 
the formation of pyrrolidine 192 as the major product (192:193 = 2.5:1). This ratio remained 
consistent in the presence of bulky azide sources, such as tetrabutylammonium azide.
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Indicating azide anions liberated from various sources, displayed a similar preference for 
nucleophilic attack at the least hindered carbon of the aziridine ring.
56
 We further sought to 
investigate the effect of a larger counter ion on the regioselectivity of the ring-opening reaction. 
This was to be accomplished by iodide abstraction and exchange for the non-nucleophillic 
hexafluoroantimonate ion. Treating β–iodoamine 189 with 1.2 equivalents of AgSbF6 resulted in 
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the formation of the crystalline product 194 (95% yield), which was further reacted with sodium 
azide (1.5 equivalents, DMF, 50 °C) (Figure 12). Analysis of the products by 
1
H NMR indicated 
the formation of 192 and 193 in a 2.5:1 ratio. Thus, the azide anion preferentially attacks at the 
sterically least hindered center, independent of iodide or hexafluoroantimonate counter ion.  
 
Scheme 27. Synthesis β-azido amine 192 and diamine 196   
 
a) NaN3, DMF. b)  AgSbF6, THF, rt. c) 10 mol % Pd(OH)2/C, 
NH4HCO2, EtOH, 80 ºC. 
 
 With the completion of a route to model β-azido amine 192, we next sought to generate 
the desired diamine scaffold utilizing a global reduction strategy. To accomplish this, we first 
investigated several strategies utilizing palladium on carbon (5% and 10%) to generate diamine 
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196, resulting from concomitant azide reduction and benzyl deprotection (Scheme 27). In a 
majority of instances, reduction of the azide function without deprotection occurred or complete 
decomposition of the product was observed. However, using Pearlman’s catalyst (Pd(OH)2/C) in 
conjunction with ammonium formate, we obtained diamine 196. Treating  192 with 10 mol % 
Pd(OH)2/C in the presence of  12.5 equivalents of NH4HCO2 at 80 ºC provided 196 in 90% 
yield.
57
  These results indicate that Pd(OH)2/C serves as a superior catalyst when both N-
debenzylation and azide reduction are desired. 
 
Figure 12. X-ray crystal structure of aziridinium 194  
4.4 DIVERSITY BY INCORPORATION OF C3 SUBSTITUTION 
Having established a synthetic route towards pyrrolidine 196, we next focused on the generation 
of various pyrrolidine scaffolds for DOS. To demonstrate the versatility of this approach and 
integrate heterocycles with multifunctional sites, we initially identified 203-208 as potential 
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substrates.  The work presented within this section, describes the alternative C3 substitutions 
made in place of the phenyl group (Scheme 28).  
 The preparation of allylic alcohols 203-208 from simple compounds is displayed in 
Scheme 28. 1-(Triisopropylsilyl)pyrrole-3-carbaldehyde (197) was prepared according to 
literature procedure.
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 Knoevenagel condensation of aldehyde 197 with monoethylmalonate, 
followed by benzyl protection and DIBAL-H reduction afforded allyl alcohol 203 in 73% yield 
over 3 steps.  Unexpectedly, simultaneous TIPS deprotection was found to occur during 
condensation.  A similar sequence of condensation, protection and reduction generated 204 in 
55% yield over 3 steps. Simple reduction of trans-3-(2-furyl)acrolein (200) afforded desired 
alcohol 206 in 91% yield. Allyl alcohols 205, 207, and 208 were synthesized through a two-step 
protocol of condensation and reduction from aldehydes 199, 201, and 202 in acceptable yields 
(66-75% yield). 
 
Scheme 28. Preparation of allylic alcohols 
 
a) monoethylmalonate, DMAP, piperdine, DMF, rt. b) BnBr, NaH, DMF,  0 °C to rt. c) DIBAL, CH2Cl2, -78 °C. d) 
BnBr, K2CO3, DMF, 0 °C to rt. DMAP = 4-Dimethylaminopyridine. 
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Following the procedure previously developed for the incorporation of cinnamyl 
aldehyde (178) into the pyrrolidine scaffold (196), we next sought to generate the corresponding 
aldehydes from allylic alcohols 203-208. The reaction of allylic alcohols 203-208 with 1.2 
equivalents of allyl bromide and 1.3 equivalents of NaH in THF, provided bis(allyl) ethers 211-
216 in 89-99% yield (Table 5). Subsequent iridium catalyzed isomerization of ethers 211-215 
(0.5 mol % [Ir(COE)Cl]2, 3 mol % PCy3, 2 mol % NaBPh4, CH2Cl2/Acetone) provided 217-221 
in 67-85% yield, with the exception of pyridine di(allyl) ether 216. Interestingly, iridium-
catalyzed deallylation of 216 proceeded to completion in less than a minute, and provided allylic 
alcohol 205 in 99% yield. Facile O-deallylation of bis(allyl) ether 216 can be attributed to the 
rapid formation of cationic tetrasubstituted complex 227.  Coordination of the pyridine ring to 
the metal center, deactivates the triphosphene catalyst (222) towards isomerization enabling the 
competing SN2’-type reaction. Nucleophilic of attack of chlorine, present in the reaction mixture 
results in the formation of allylic alcohol 229 and allyl chloride (230) (Scheme 29). 
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Table 5. Iridium catalyzed isomerization of bis(allyl) ethers 211-216 
 
a 
Isolated yields. COE = cyclooctene. 
 
 
Scheme 29. Iridium-catalyzed deallylation 
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We next examined the conversion of allyl vinyl ethers 217-221 into the corresponding 
diamines, according to our previously determined protocol. Claisen rearrangement of 217-221 
afforded γ,δ-unsaturated aldehydes 232-236 under thermal conditions.  Reductive amination of 
the pending aldehydes followed by iodocyclization, and azide substitution ultimately afforded β-
azido pyrrolidines 238-241 (Table 6).
46, 55,57,59,60  
 We were unable to isolate  β-azido pyrrolidine 
237 following treatment with 2 equivalents of benzylamine (NaHB(OAc)3, AcOH, CH2Cl2). This 
may be explained by the reactive nature of the pyrrole ring, which underwent frequent 
decomposition. Reductive deprotection of β-azido pyrrolidines 239 and 240 utilizing Pearlman’s 
catalyst provided 244 and 245 in 91% and 93% yield, respectively. However, global reductive 
deprotection of 4-hydroxybenzyl derivative 238 could not accurately be reproduced utilizing our 
standard reductive deprotection conditions (10 mol % Pd(OH)2/C, 12.5 equivalents NH4HCO2, 
EtOH, 80 °C).  Pearlman’s catalyst was additionally found to effect the dehalogenation of aryl 
halide 241 with concomitant reduction to afford diamine 196.   In all cases, decreased catalyst 
loading produced similar results, with 100% conversion of 241 to model diamine 196. It was 
therefore concluded, that palladium hydroxide on carbon in the presence of ammonium formate 
effectively catalyzes dehalogenation of aryl bromides at an appreciable rate.  
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Table 6. Synthesis of C3 substituted diamines 
 
a
 Isolated yields. 
b
 Not determined. Bn = benzyl, NIS = N-iodosuccinimide. 
4.5 ASYMMETRIC SYNTHESIS OF β-IODO PYRROLIDINE SCAFFOLD 
The enantio- and diastereoselective Ru (II)-catalyzed Claisen rearrangement of unactivated allyl 
vinyl ethers has recently been investigated in our laboratory (Figure 13).
47
 Having developed a 
racemic synthesis of diamines 196, 244, and 245 we sought to develop an asymmetric route to β–
iodo amine 253 and decipher the configuration at the newly formed stereocenter (Scheme 30).   
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Figure 13. Asymmetric Ru (II)-catalyzed [3,3]-sigmatropic rearrangement of general allyl vinyl ether (174) 
 
The mechanism of the transformation of allyl vinyl ether 174 to anti-product 247 
involves the formation of π–allyl intermediate (246), which undergoes enantioselective attack by 
a ruthenium-bound enolate (Figure 13). Oxidative addition into the C-O σ-bond of allyl vinyl 
ether 174 is facilitated by the presence of Lewis acids, through oxygen coordination.  In 
agreement with previous reports, the ruthenium-catalyzed rearrangement of allylic vinyl ether 
179, employing 5 mol % CpRu(CH3CN)3PF6 and 5 mol % B(OPh)3 as the Lewis acid provided 
anti-[3,3] product 250 and [1,3]-product 251 (250:251 = 5:1, 250anti:250syn = 10:1, 92% ee) in 
91% yield (eq 7). 
 
 
 
Reductive amination of (2R, 3R)-2-methyl-3-phenylpent-4-enal (250) with benzylamine 
in the presence of sodium triacetoxyborohydride, followed by iodocyclization with N-
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iodosuccinimide provided (2S,3R,4R)-β–iodo amine 253 (Scheme 30). NOESY analysis revealed 
no correlation between H2 and H3, suggesting an arrangement which diminishes steric 
interactions between the iodo and phenyl substituents. The relative stereochemistry of C2 and C3 
is also in agreement with previous X-ray data (Figure 12).   
Scheme 30. Synthesis of β–iodo amine 253 
 
a) benzylamine, NaHB(OAc)3, AcOH, CH2Cl2. b) NIS, THF. NIS = 
N-iodosuccinimide.  
4.6 CONCLUSIONS 
We have presented a novel route to the synthesis of diverse pyrrolidine scaffolds for diversity-
oriented synthesis. This route involves the incorporation of a previously developed  Ir(I)-based 
catalyst systems for selective isomerization of bis(allyl) ether substrates, as well as, reductive 
amination, iodocyclization, azide formation, and reductive deprotection protocols developed 
herein.
46
  Additionally, an asymmetric approach to the synthesis of (2S,3R,4R)-β–iodo amine 253 
has been presented using selective Ru(II)-catalyzed Claisen rearrangement methodology.
47
 
Pyrrolidine scaffolds present an avenue of interest, since to our knowledge no other diversity-
oriented syntheses have previously been developed. Furthermore, our scaffolds are capable of 
further diversification through the incorporation of various electrophilic reagents.  
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5.0  EXPERIMENTAL 
General Information: All reactions were performed in dry glassware under an atmosphere of 
oxygen-free nitrogen using standard inert atmosphere techniques for the manipulation of both 
solvents and reagents. Anhydrous solvents were obtained by passage through successive 
alumina- and Q5-packed columns on a solvent purification system.  Acetone was distilled from 
Drierite
®
 and stored under nitrogen over 4 Å MS. Sodium hydride (60% dispersion in mineral 
oil) and sodium triacetoxyborohydride were purchased from Sigma-Aldrich, and used directly. 
Palladium hydroxide (10% on carbon) and ammonium formate were purchased from Alfa-Aesar. 
Allyl bromide was purchased from Sigma-Aldrich and purified by distillation over CaH2. 
Cinnamyl alcohol, [Ir (COE) Cl] 2, and PCy3 were purchased from Strem, and were stored and 
weighed out in a nitrogen-filled glove box.  NMR spectra were recorded on a Bruker Avance-
400 (400 MHz) spectrometer with chemical shifts reported relative to residual CHCl3 (7.26 ppm) 
for 
1
H and CDCl3 (77.00 ppm) for 
13
C NMR spectra.  Infrared spectra were recorded on a 
Nicolet Avatar 360 FT-IR spectrometer. High resolution mass spectra were obtained on a VG-
7070 or Fisons Autospec high-resolution magnetic sector mass spectrometer. Analytical thin 
layer chromatography (TLC) was performed on EM Reagent 0.25 mm silica gel 60-F plates.  
Flash chromatography was performed over EM silica gel 60 (230-240 mesh). The anti Claisen 
adduct 250 utilized in the asymmetric synthesis was prepared according to literature procedure.
47
 
The enantiomer ratio was determined by chiral stationary phase GLC (Varian Chirasil-Dex CB 
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WCOT Fused Silica CP 7502 Column, 25m x 0.25 mm) and was assigned by comparison to 
previous reports.
47
  
5.1 EFFORTS TOWARDS THE SYNTHESIS OF MARINEOSIN A  
2-((1-Benzyl-1H-pyrrol-2-yl)methylene)propane-1,3-diyl diacetate (80): 
Acetyl chloride ( 3.0 equiv, 0.3 mL, 4.14 mmol) was added over 15 minutes 
to a solution of pyridine (4.0 equiv, 0.45 mL, 5.52 mmol) and 2-((1-benzyl-1H-pyrrol-2-
yl)methylene)propane-1,3-diol (79) (335 mg, 1.38 mmol) in THF (3.0 mL) at 0°C . The reaction 
was then warmed to ambient temperature and stirred for 12 h. The resulting solution was 
quenched with 10 mL of water and the aqueous and organic portions were separated. The 
aqueous portion was extracted with Et2O (3 x 10 mL) and the combined organic layers were 
washed with aqueous CuSO4, water, and brine. The organic portion was dried over anhydrous 
Na2SO4, concentrated and purified by flash chromatography (40% ethyl acetate in hexanes) to 
afford 361 mg of the title compound (80%) as a light yellow oil. 
1
H NMR (400 MHz, CDCl3):  
7.32-7.27 (m, 3H), 7.01-6.99 (m, 2H), 6.77 (app s, 1H), 6.47 (app s, 1H), 6.31 (app s, 1H), 6.22 
(app s, 1H), 5.10 (s, 2H), 4.87 (s, 2H), 4.64 (s, 2H), 2.08 (s, 3H), 2.01 (s, 3H); 
13
C NMR (100 
MHz, CDCl3):  170.9, 170.7, 137.7, 128.8, 127.6, 126.4, 123.8, 122.9, 111.9, 108.8, 66.8, 
61.52, 50.8, 20.9. 
2
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2-((4R,5R)-1-Methyl-4,5-diphenyl-4,5-dihydro-1H-imidazol-2-yl)pyridine 
(90): 
1
H NMR (400 MHz, CDCl3):  8.71 (ddd, J = 1.0, 2.0, 5.0 Hz, 1H), 8.10 
(td, J = 1.0, 7.5 Hz, 1H), 7.81 (dt, J = 2.0, 8.0 Hz, 1H), 7.32 (m, 11H), 4.99 (d, 
J = 10.5, 1H), 4.36 (d, J = 10.5, 1H), 2.99 (s, 3H).  This compound was prepared according to 
literature procedure and matches the characterization data provided in the following the 
publication: Davenport, A. J.; Davies, D. L.; Fawcett, J.; Russell, D. R., J. Chem. Soc. Perk. T 1 
2001,  (13), 1500-1503. 
 
(Z)-2-((1-Benzyl-1H-pyrrol-2-yl)methylene)-4-methyl-5-oxo-5-(1H-
pyrrol-1-yl)pentyl acetate (88): [Cp*Ru(CH3CN)3]PF6 (5 mol %, 15.4 mg, 
0.03 mmol) and ligand 90 (5 mol %, 9.6 mg, 0.03 mmol) were added to THF 
(1.22 mL) inside a nitrogen-filled glovebox, and the mixture was periodically 
agitated over 15 minutes. The resulting solution was then transferred to a mixture containing allylic 
diacetate 80 (200 mg, 0.61 mmol), (Z)-1-(1-((trimethylsilyl)oxy)prop-1-en-1-yl)-1H-pyrrole (85) 
(1.05 equiv, 125 mg, 0.64 mmol), and B(OPhpNO2)3 (15 mol %, 38.9 mg, 0.09 mmol ). The solution 
was removed from the glovebox and stirred at ambient temperature for 24 h. After 24 h the reaction 
mixture was concentrated under a stream of N2, diluted with pentanes and filtered through a pad of 
Florisil®. The product was purified by flash chromatography (30% ethyl acetate in hexanes) to afford 
21 mg of the title compound (9%) as a light yellow oil. 
1
H NMR (400 MHz, CDCl3):  8.17 (d, J = 
9.0 Hz, 1H), 7.31-7.28 (m, 3H), 6.98 (d, J = 7.0 Hz, 2H), 6.91 (d, J = 9.0 Hz, 1H), 6.71 (t, J = 1.5 
Hz, 1H), 6.29-6.27 (m, 3H), 6.19-6.16 (m, 2H),  5.00 (s, 2H), 4.90 (d, J = 12.5 Hz, 1H), 4.79 (d, 
J = 12.5 Hz, 1H), 3.32 (m, 1H), 2.77 (m, 1H), 2.29 (m, 1H), 2.09 (s, 3H), 1.18 (d, J = 6.5Hz, 
3.0H); 
13
C NMR (100 MHz, CDCl3):  173.8, 171.1, 137.8, 131.3, 128.8, 128.0, 127.5, 126.4, 
126.2, 123.0, 122.3, 119.0, 115.6, 113.3, 110.9, 108.3, 63.1, 50.7, 39.9, 37.1, 20.9, 17.5. 
2
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2-((1-(Triisopropylsilyl)-1H-pyrrol-2-yl)methylene)propane-1,3-diyl 
diacetate (84): Acetyl chloride (3.0 equiv, 0.63 mL, 8.73 mmol) was added 
over 15 minutes to a solution of pyridine (4.0 equiv, 0.95 mL, 11.6 mmol) and 2-((1-
(triisopropylsilyl)-1H-pyrrol-2-yl)methylene)propane-1,3-diol (83) (900 mg, 2.91 mmol) in THF 
(15 mL) at 0°C . The reaction was then warmed to ambient temperature and stirred for 12 h. The 
resulting solution was quenched with 30 mL of water and the aqueous and organic portions were 
separated. The aqueous portion was extracted with Et2O (3 x 15 mL) and the combined organic 
layers were washed with aqueous CuSO4, water, and brine. The organic portion was dried over 
anhydrous Na2SO4, concentrated and purified by flash chromatography (30% ethyl acetate in 
hexanes) to afford 1.01 g of the title compound (88%) as a light yellow oil. 
1
H NMR (400 MHz, 
CDCl3):  6.89 (d, J = 1.0 Hz, 1H), 6.74 (s, 1H), 6.33 (d, J = 2.0 Hz, 1H), 6.27 (t, J = 2.0 Hz, 
1H), 4.87 (s, 2H), 4.72 (s, 2H), 2.09 (s, 3H), 2.08 (s, 3H), 1.53-1.45 (m, 3H), 1.08 (d, J = 5.5 Hz, 
18H). 
1
 
 
(S,E)-6-Methyl-8-((1-(triisopropylsilyl)-1H-pyrrol-2-yl)methylene)-
6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepin-5-one (89): 
[Cp*Ru(CH3CN)3]PF6 (5 mol %, 6.40 mg, 0.01 mmol) and ligand 90 (5 mol 
%, 4.0 mg, 0.01 mmol) were added to THF (0.5 mL) inside a nitrogen-filled 
glovebox, and the mixture was periodically agitated over 15 minutes. The resulting solution was then 
transferred to a mixture containing allylic diacetate 84 (100 mg, 0.25 mmol), (Z)-1-(1-
((trimethylsilyl)oxy)prop-1-en-1-yl)-1H-pyrrole (85) (1.05 equiv, 52 mg, 0.27 mmol), and 
B(OPhpNO2)3 (15 mol %, 16.2 mg, 0.04 mmol). The solution was removed from the glovebox and 
stirred at ambient temperature for 24 h. After 24 h the reaction mixture was concentrated under a 
stream of N2, diluted with pentanes and filtered through a pad of Florisil
®. The resulting product was 
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purified by flash chromatography (15% ethyl acetate in hexanes) to afford the title compound as a 
white solid.  Recrystallization of 89 from Et2O/Hexanes yielded crystals suitable for X-ray 
diffraction analysis (Appendix A) ;
 1
H NMR (400 MHz, CDCl3):  7.43 (app s, 1H), 6.79 (app s, 
1H), 6.32-6.03 (m, 5H), 3.78 (d, J = 15 Hz, 1H), 3.58 (d, J = 15 Hz, 1H), 3.20 (m, 1H), 2.76 (m, 
2H), 1.42 (m, 3H), 1.36 (d, J = 6.5 Hz, 3H), 1.03 (d, J = 7.5 Hz, 18H); 
13
C NMR (100 MHz, 
CDCl3):  173.2, 133.7, 132.2, 131.8, 125.8, 119.9, 119.3, 113.1, 111.2, 110.7, 109.9, 37.8, 36.8, 
36.2, 18.1, 17.9, 12.9. 
2
 
 
2-Benzylidenepropane-1,3-diyl diacetate (76): Acetyl chloride (3.0 equiv, 
0.21 mL, 2.91 mmol) was added over 15 minutes to a solution of pyridine 
(4.0 equiv, 0.32 mL, 3.88 mmol) and 2-benzylidenepropane-1,3-diol (75) (159 mg, 0.97 mmol) 
in THF (5 mL) at 0°C . The reaction was then warmed to ambient temperature and stirred for 12 
h. The resulting solution was quenched with 10 mL of water and the aqueous and organic 
portions were separated. The aqueous portion was extracted with Et2O (3 x 10 mL) and the 
combined organic layers were washed with aqueous CuSO4, water, and brine. The organic 
portion was dried over anhydrous Na2SO4, concentrated and purified by flash chromatography 
(20% ethyl acetate in hexanes) to afford 216 mg of the title compound (90%) as a light yellow 
oil. 
1
H NMR (400 MHz, CDCl3):  7.37-7.23 (m, 5H), 6.84 (s, 1H), 4.78 (s, 2H), 4.74 (s, 2H), 
2.11 (s, 3H), 2.08 (s, 3H). 
1
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N5, N5, N10, N10-Tetramethyl-5H,10H-dipyrrolo[1,2-a:1',2'-d]pyrazine-
5,10-diamine (103): 
1
H NMR (400 MHz, CDCl3):  6.96 (dd, J = 2.5, 1.0 
Hz, 2H), 6.26 (dd, J = 4.5, 4.0 Hz, 2H), 6.17 (m, 2H), 5.87 (s, 2H), 2.22 (s, 
12H).  This compound was prepared according to literature procedure and matches the 
characterization data provided in the following the publication: Muchowski, J. M.; Hess, P. 
Tetrahedron Lett. 1988, 29 (7), 777-780. 
 
(9-Iodonon-1-yn-1-yl)trimethylsilane (108): n-Butyllithium (2.0 equiv, 
56 mL, 78.5 mmol) was added drop wise to a solution of non-8-yn-1-ol 
(106) (5.5 g, 39.2 mmol) in THF (131 mL) at -78 °C, and the resulting 
mixture was stirred for 1 h. After this time, chlorotrimethylsilane (2.5 equiv, 12.5 mL, 98 mmol) 
was added and the reaction was stirred an additional 30 min at -78 °C. The resulting solution was 
then warmed to 0 °C and slowly quenched with 45 ml of water. The aqueous portion was 
extracted with Et2O (3 x 50 mL) and the combined organic layers were washed with water, 2 M 
HCl, saturated aqueous NaHCO3, and brine. The organic portion was dried over anhydrous 
Na2SO4 and concentrated. The resulting residue was dissolved in CH2Cl2 (197 mL), and 
triphenylphosphine (1.2 equiv, 12.4 g, 47.1 mmol) and imidazole (2.0 equiv, 5.33 g, 78.4 mmol) 
were added at ambient temperature. Then mixture was then cooled to 0 °C prior to the addition 
of I2 (1.2 equiv, 11.95 g, 47.1 mmol) and stirred for 1 h.   After 1 h, the reaction was quenched 
with saturated aqueous Na2S2O3 until the solution changed from red to clear. The aqueous 
portion was extracted with CH2Cl2 (3 x 50 mL), concentrated, diluted with hexanes and filtered 
through a pad of Celite
®
. 
1
H NMR (400 MHz, CDCl3):  3.19 (t, J = 4.5 Hz, 2H), 2.21 (t, J = 9.5 
Hz, 2H), 1.80 (m, 2H), 1.41-1.26 (m, 8H), 0.1 (s, 9H). 
1
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5-(9-(Trimethylsilyl)non-8-yn-1-yl)-1H-pyrrole-2-carbaldehyde (109): n-
Butyllithium (3.0 equiv, 18.1 mL, 21.7 mmol) was added to a solution of 
azafulvene dimer 103 (1.77 g, 7.23 mmol) in THF (145 mL) at -15 °C, and 
stirred for 1.5 h. The resulting deep purple solution was cooled to -60 °C and a solution of 
iodoalkyne 108 (2.2 equiv, 5.13 g, 15.9 mmol) in THF (5 mL) was added. The pale yellow 
solution was warmed to ambient temperature and stirred 12 h, during which the solution became 
orange in color. After this time, 75 mL of saturated aqueous NaHCO3 was added and the reaction 
solution was further diluted with THF (50 mL) and heated to 80 °C. The reaction was refluxed 
for 3 h at 80 °C, cooled to ambient temperature and poured into a solution of aqueous NaHCO3 
(50 mL). The aqueous portion was extracted with Et2O (3 x 50 mL), and the combined organic 
layers were washed with water and brine. The organic portion was dried over anhydrous Na2SO4, 
concentrated and purified by flash chromatography (30% ethyl acetate in hexanes) to afford 1.32 
g of the title compound (32%) as a yellow oil. 
1
H NMR (400 MHz, CDCl3):  9.37 (s, 1H), 9.31 
(broad s, 1H), 6.89 (t, J = 3.0 Hz, 1H), 6.08 (t, J = 3.0 Hz, 1H), 2.66 (t, J = 7.5 Hz,  2H), 2.22 (t, 
J = 7.0 Hz, 2H), 1.52 (m, 2H), 1.40 (m, 8H), 0.1 (s, 9H). 
1
   
 
1-Benzyl-2-(non-8-yn-1-yl)-5-vinyl-1H-pyrrole (114): Potassium carbonate 
(2.0 equiv, 554 mg, 4.0 mmol) was added to a solution of  1-benzyl-2-(9-
(trimethylsilyl)non-8-yn-1-yl)-5-vinyl-1H-pyrrole (113) (757 mg, 2.0 mmol) in 
MeOH/THF (10 mL/4 mL) at ambient temperature and stirred 2 h. The resulting solution was 
diluted with Et2O (20 mL), filtered through a pad of Celite® then purified by flash 
chromatography (10% ethyl acetate in hexanes) to afford 480 mg the title compound (78%) as a light 
yellow oil.   
1
H NMR (400 MHz, CDCl3):  7.33-7.22 (m, 3H), 6.91 (d, J = 7.5 Hz), 6.42 (m, 2 
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H), 5.96 (d, J = 3.0 Hz, 1H), 5.42 (d, J = 17 Hz, 1H), 5.11 (s, 2H), 4.88 (d, J = 11 Hz), 2.45 (t, J 
= 7.5 Hz, 2H), 2.15 (t, J = 7.0 Hz, 2H), 1.92 (t, J = 3.0 Hz, 1H), 1.56-1.46 (m, 2H), 1.34-1.28 (m, 
8H). 
1
 
 
(E)-2-(3-(Allyloxy)prop-1-en-1-yl)-1-benzyl-5-(non-8-yn-1-yl)-1H-
pyrrole (122): (E)-3-(1-Benzyl-5-(non-8-yn-1-yl)-1H-pyrrol-2-yl)prop-2-
en-1-ol (121) (100 mg, 0.30 mmol) was slowly added to a suspension of 
NaH (1.3 equiv, 16.0 mg, 0.39 mmol)  in THF (20 mL) at 0 °C. The resulting mixture was 
warmed to ambient temperature and stirred for 1.5 h. After this time, allyl bromide (1.2 equiv, 
30.0 µL, 0.36 mmol) was added and the reaction was stirred 3 h before being quenched with 25 
mL of water. The aqueous portion was extracted with Et2O (3 x 40 mL) and the combined 
organic layers were washed with water, and brine. The organic portion was dried over anhydrous 
Na2SO4, concentrated and purified by flash chromatography (20% ethyl acetate in hexanes) to 
afford 50 mg of the title compound (44%) as a light yellow oil.  
1
H NMR (400 MHz, CDCl3):  
7.31-7.22 (m, 3H), 6.91-6.89 (m, 2H), 6.38 (d, J = 3.5 Hz, 1H), 6.35 (d, J = 15 Hz, 1H), 6.03-
5.81 (m, 3 H), 5.14-5.10 (m, 4H), 4.09 (d, J = 5.5 Hz, 2H), 3.89 (d, J = 5.5 Hz, 2H), 2.44 (t, J = 
7.5 Hz, 2 H), 2. 14 (dt, J = 2.5, 4.0 Hz, 2H), 1.92 (t, J = 3.0 Hz, 1H), 1.56-1.46 (m, 2H), 1.36-
1.26 (m, 8H). 
1
 
 
5-(Non-8-en-1-yl)-1H-pyrrole-2-carbaldehyde (127): 
1
H NMR (400 MHz, 
CDCl3):  9.58, (broad s, 1H) 9.53 (s, 1H), 6.89 (appt s, 1H), 6.08 (appt s, 1H), 
5.84-5.75 (m, 1H), 5.01-4.92 (m, 2H), 2. 66 (t, J = 7.5 Hz, 2H), 2.05-2.00 (m, 2H), 
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1.67-1.63 (m, 3H), 1.39-1.26 (m, 10H). This compound was prepared according to the following 
the publication: Muchowski, J. M.; Hess, P. Tetrahedron Lett. 1988, 29 (7), 777-780. 
 
1-Benzyl-2-(non-8-en-1-yl)-5-vinyl-1H-pyrrole (128): Potassium 
hexamethyldisilazide (1.3 equiv, 6.14 mL, 3.07 mmol) was added to a solution of 
methyltriphenylphosphonium bromide (1.5 equiv, 1.26 g, 3.54 mmol) in THF (35 
mL) at ambient temperature, and was stirred vigorously for 30 min. After 30 min, a solution of 
aldehyde 127 (730 mg, 2.36 mmol) in THF (24 mL) was added and the reaction was stirred an 
additional 1 h. The resulting solution was poured into 130 mL of Et2O: water (1:1) and the 
aqueous and organic layers were separated. The aqueous portion was extracted with Et2O (3 x 50 
mL) and the combined organic layers were washed with water, and brine. The organic portion 
was dried over anhydrous Na2SO4, concentrated and purified by flash chromatography (20% 
ethyl acetate in hexanes) to afford 551 mg of the title compound (76%) as a light yellow oil.  
1
H 
NMR (400 MHz, CDCl3):  7.32-7.18 (m, 3H), 6.92-6.90 (m, 2H), 6.44-6.39 (m, 2H), 5.96 (d, J 
= 3.5Hz, 1H), 5.79 (m, 1H), 5.42 (dd, J = 1.5, 150.5 Hz, 1H), 5.11 (s, 2H), 5.00-4.89 (m, 3H), 
2.45 (t, J = 7.5 Hz, 2H), 2.00 (m, 2H), 1.53 (m, 2H), 1.35-1.25 (m, 8H). 
1
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5.2  DEVELOPMENT OF PYRROLIDINE SCAFFOLDS FOR DIVERSITY-
ORIENTED SYNTHESIS 
 
 
General Procedure for the Formation of Di(Allyl) Ethers (General Procedure A): Sodium 
Hydride (1.3 equiv, 60% suspension in mineral oil) was added to a solution of alcohol A (1.0 
equiv) in THF (0.8 M) at 0 °C, and the solution stirred 30 minutes. Allyl bromide B (1.2 equiv) 
was added and the resulting suspension was warmed to ambient temperature and stirred an 
additional 3 hrs. The reaction mixture was slowly quenched with a saturated solution of NH4Cl 
and extracted with Et2O. Combined organic extracts were dried over anhydrous Na2SO4 and 
concentrated.  The crude product was further purified by flash chromatography. 
 
 
General Procedure for the Formation Allyl Vinyl Ethers (General Procedure B): 
[Ir(COE)Cl]2 (0.5 mol %), PCy3 (3 mol %) and NaBPh4 (2 mol %) were combined in a nitrogen-
filled glovebox. Immediately after removal from the glovebox, a solution of CH2Cl2/acetone (0.6 
M, 30:1) was added and the resulting red-orange solution was stirred 5 min at ambient 
temperature. Di(Allyl) ether A (1 equiv) was added to the catalyst solution in a minimal amount 
of CH2Cl2 and the reaction was monitored by TLC (1-30 min.). The reaction mixture was 
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concentrated under a steam of N2, diluted with pentanes and the resulting heterogeneous mixture 
was filtered through a pad of Florisil
®
. The resulting solution was then concentrated and purified 
by flash chromatography. 
 
 
General Procedure for the Formation of γ, δ-Unsaturated Aldehydes (General Procedure 
C):  Allyl vinyl ether A (1.0 equiv) was added to toluene (0.5 M) and the reaction was heated to 
80 ºC and stirred for 12 hrs. The resulting solution was then concentrated and purified by flash 
chromatography. 
 
 
General Procedure for the Formation of γ, δ-Unsaturated Amines (General Procedure D): 
Aldehyde A (1.0 equiv), NaHB(OAc)3 (2.0 equiv), benzylamine (2.0 equiv), and acetic acid (1.0 
equiv)  were added to CH2Cl2 (0.1M) at 0 ºC. After 15 minutes the reaction was warmed to rt and 
stirred an additional 12 hrs. The resulting solution was quenched with sodium carbonate (0.1M) 
and extracted with CH2Cl2.  Combined organic extracts were dried over anhydrous Na2SO4 and 
concentrated.  The crude product was further purified by flash chromatography. 
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General Procedure for the Formation of β-Iodo Pyrrolidines (General Procedure E):  
Pentenamine A (1.0 equiv) and NIS (1.1 equiv) were added to THF (0.3 M) at ambient 
temperature and the reaction was stirred for 1 hr. The resulting mixture was then concentrated 
and immediately purified by flash chromatography. 
 
 
General Procedure for the Formation of β-Azido Pyrrolidines and 3-AzidoPiperdines 
(General Procedure F):  Pyrrolidine A (1.0 equiv) and NaN3 (1.5 equiv) were added to DMF 
(0.12 M) and the reaction was heated to 50 ºC and stirred for 1h.  The resulting solution was 
diluted with water (0.1M) and extracted with CH2Cl2. Combined organic layers were dried over 
anhydrous Na2SO4 and concentrated.  The crude product was then purified by flash 
chromatography. 
 
 68 
 
General Procedure for the Formation of β-Amino Pyrrolidines (General Procedure G): 
Pyrrolidine A (1 equiv) was added drop wise to a slurry of Pd(OH)2/C (10 mol %) and 
NH4HCO2 (12.5 equiv) in EtOH (0.5 M) at rt. After 30 minutes, the reaction was warmed to 80 
ºC and refluxed for an additional 4 hrs.  The mixture was then cooled and filtered through a pad 
of Celite
®
 eluting with MeOH. The resulting viscous oil was purified by reverse phase MPLC. 
 
(E)-(3-(Allyloxy)prop-1-en-1-yl)benzene (179): General   procedure   A   was 
followed employing 2.87 mL of cinnamyl alcohol (22.3 mmol), 1.16 g  of NaH 
(29 mmol), and 2.33 mL of allyl bromide (26.7 mmol) in 30 mL of THF. The resulting product 
was purified by flash chromatography (10% diethyl ether in hexanes) to afford 3.90 g of the title 
compound (93%) as a colorless oil.  This compound matches the characterization data provided 
in the following the publication: Kerrigan, N. J.; Bungard, C. J.; Nelson, S. G. Tetrahedron 2008 
(64) 6863-6869. 
 
 (E)-2-(3-(Allyloxy)prop-1-en-1-yl)furan (213): General   procedure   A   was 
followed employing 1.2 g of (E)-3-(furan-2-yl)prop-2-en-1-ol (10 mmol), 521mg 
of NaH (13 mmol), and 1.0 mL of allyl bromide (12 mmol) in 12.5 mL of THF. The resulting 
product was purified by flash chromatography (10% diethyl ether in hexanes) to afford 1.6 g of 
the title compound (99%) as a colorless oil.  This compound matches the characterization data 
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provided in the following the publication: Geherty, M. Catalytic Asymmetric Claisen 
Rearrangements. The Development of Ru(II)-Catalyzed Formal [3,3] Sigmatropic 
Rearrangements and Related Enolate Allylation Reactions. Ph.D. Thesis, University of 
Pittsburgh, December 2012. 
 
(E)-1-(3-(Allyloxy)prop-1-en-1-yl)-3-methoxybenzene (214): General   
procedure   A   was followed employing 1.73 g of (E)-3-(3-methoxyphenyl)prop-
2-en-1-ol (11 mmol), 557 mg of NaH (14.3 mmol), and 1.14 mL of allyl bromide 
(13.2 mmol) in 13 mLof THF. The resulting product was purified by flash chromatography (10% 
diethyl ether in hexanes) to afford 2.2 g of the title compound (99%) as a colorless oil.  This 
compound matches the characterization data provided in the following the publication: Geherty, 
M. Catalytic Asymmetric Claisen Rearrangements. The Development of Ru(II)-Catalyzed 
Formal [3,3] Sigmatropic Rearrangements and Related Enolate Allylation Reactions. Ph.D. 
Thesis, University of Pittsburgh, December 2012. 
 
(E)-1-(3-(Allyloxy)prop-1-en-1-yl)-4-bromobenzene (215): General   
procedure   A   was followed employing 2.10 g of (E)-3-(4-
bromophenyl)prop-2-en-1-ol (10 mmol), 521 mg of  NaH (13.1 mmol), and 
1.0 mL of allyl bromide (12 mmol) in 12 mL of THF. The resulting product was purified by flash 
chromatography (50 % diethyl ether in hexanes) to afford 2.33 g of the title compound (92%) as 
a colorless oil.  This compound matches the characterization data provided in the following the 
publication: Geherty, M. Catalytic Asymmetric Claisen Rearrangements. The Development of 
Ru(II)-Catalyzed Formal [3,3] Sigmatropic Rearrangements and Related Enolate Allylation 
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Reactions. Ph.D. Thesis, University of Pittsburgh, December 2012. 
 
 (E)-3-(3-(Allyloxy)prop-1-en-1-yl)-1-benzyl-1H-pyrrole (211): General   
procedure   A   was followed employing 165 mg of (E)-3-(1-benzyl-1H-pyrrol-3-
yl)prop-2-en-1-ol (0.77 mmol), 40.1 mg of NaH (1.0 mmol), and 80 µL of allyl 
bromide (0.92 mmol) in 4 mL of THF. The resulting product was purified by flash 
chromatography (50 % diethyl ether in hexanes) to afford 180 mg of the title compound (92%) as 
a light yellow oil.
 1
H NMR (400 MHz, CDCl3):  7.42-7.27 (m, 3H), 7.13 (d, J = 7.0 Hz, 2H), 
6.64 (t, J = 8.0 Hz, 1H), 6.63 (m, 1H), 6.50 (s, 1H), 6.33 (m, 1H), 6.01-5.92 (m, 2H), 5.33 (d, 
J = 1.5 Hz, 1H), 5.29 (d, J = 1.5 Hz, 1H), 5.18 (s, 2H), 4.10 (d, J = 7.0 Hz, 2H), 4.02 (d, J = 6.0 
Hz, 2H). 
 
 (E)-1-(3-(Allyloxy)prop-1-en-1-yl)-4-(benzyloxy)benzene (212): General   
procedure   A   was followed employing 1.0 g of (E)-3-(4-
bromophenyl)prop-2-en-1-ol (4.16 mmol), 217 mg of NaH (5.40 mmol), 
and 0.432 mL of allyl bromide (5 mmol) in 13 mL of THF. The resulting product was purified by 
flash chromatography (8 % ethyl acetate in hexanes) to afford 1.6 g of the title compound 
(100%) as a colorless oil.
 1
H NMR (400 MHz, CDCl3):  7.42-7.31 (m, 5H), 6.92 (d, J = 9.0 Hz, 
2H), 6.54 (d, J = 15.5 Hz, 1H), 6.16 (dt, J = 6.5, 6.0 Hz, 1H), 5.95 (m, 1H), 5.30 (dd, J = 1.0, 16 
Hz, 1H), 5.21 (d, J = 10.5 Hz, 1H), 5.06 (s, 2H), 4.13 (d, J = 6.0 Hz, 2H), 4.02 (d, J = 6.0 Hz, 
2H). 
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(E)-2-(3-(Allyloxy)prop-1-en-1-yl)pyridine (216): General   procedure   A   was 
followed employing 540 mg of (E)-3-(pyridin-2-yl) prop-2-en-1-ol (4 mmol), 208 
mg of NaH (5.2 mmol), and 0.415 mL of allyl bromide (4.8 mmol) in 5 ml of THF. The resulting 
product was purified by flash chromatography (10% ethyl acetate in hexanes) to afford 624mg of 
the title compound (89%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3):  8.55 (d, J = 4.5 Hz, 
1H), 7.62 (dt, J = 1.5, 6.0 Hz, 1H), 7.29 (d, J = 7.5 Hz, 1H), 7.12 (dt, J = 1.5, 6.0 Hz, 1H),  6.79 
(m, 2H), 5.97 (m, 1H), 5.32 (dd, J = 1.5, 15.5 Hz, 1H), 5.21 (dd, J = 1.0, 9.0 Hz, 1H), 4.22 (d, J 
= 4.5, 2H), 4.06 (d, J = 5.5 Hz, 2H).  
 
((E)-3-(((E)-Prop-1-en-1-yl)oxy)prop-1-en-1-yl)benzene (180): General 
procedure B was followed employing 2.0 g of di(allyl) ether 179 (11.5 mmol), 
52 mg of [Ir(COE)Cl]2  (0.057 mmol), 96 mg of PCy3 (0.345 mmol), and 79 mg of NaBPh4 
(0.23 mmol) in 18.4 mL of CH2Cl2/ 0.6 mL Acetone.  The resulting product was purified by 
flash chromatography (gradient elution 5% diethyl ether in hexanes) to afford 1.5 g of the title 
compound (75%) as a colorless oil.  This compounds characterization materials match the data 
provided in the following publication: Kerrigan, N. J.; Bungard, C. J.; Nelson, S. G. Tetrahedron 
2008 (64) 6863-6869. 
 
2-((E)-3-(((E)-Prop-1-en-1-yl)oxy)prop-1-en-1-yl)furan (219): General 
procedure B was followed employing 1.6 g of di(allyl) ether 213 (10 mmol), 
44.8 mg of [Ir(COE)Cl]2  (0.05 mmol), 84 mg of PCy3 (0.3 mmol), and 68.4 mg of NaBPh4 
(0.2 mmol) in 16.4 mL of CH2Cl2/ 0.6 mL Acetone.  The resulting product was purified by 
flash chromatography (5% diethyl ether in hexanes) to afford 1.1 g of the title compound (75%) 
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as a colorless oil.  This compounds characterization materials match the data provided in the 
following publication: Geherty, M. E.; Dura, R. D.; Nelson, S. G. J. Am. Chem. Soc. 2010, 132, 
11875-11877. 
 
1-Methoxy-3-((E)-3-(((E)-prop-1-en-1-yl)oxy)prop-1-en-1-yl)benzene (220): 
General procedure B was followed employing 2.32 g of di(allyl) ether 214 (11 
mmol), 49.28 mg of [Ir(COE)Cl]2  (0.055 mmol), 92.4 mg of PCy3 (0.33 
mmol), and 75.24 mg of NaBPh4 (0.22 mmol) in 17.4 mL of CH2Cl2/ 0.6 mL Acetone.  The 
resulting product was purified by flash chromatography (10% diethyl ether in hexanes) to afford 
1.95 g of the title compound (84%) as a colorless oil.  This compounds characterization 
materials match the data provided in the following publication: Geherty, M. E.; Dura, R. D.; 
Nelson, S. G. J. Am. Chem. Soc. 2010, 132, 11875-11877. 
 
1-Bromo-4-((E)-3-(((E)-prop-1-en-1-yl)oxy)prop-1-en-1-yl)benzene (221): 
General procedure B was followed employing 2.51 g of di(allyl) ether 215 
(10 mmol), 44 mg of [Ir(COE)Cl]2  (0.05 mmol), 84 mg of PCy3 (0.3 
mmol), and 68.1 mg of NaBPh4 (0.2 mmol) in 16.5 mL of CH2Cl2/ 0.5 mL Acetone.  The 
resulting product was purified by flash chromatography (10% ethyl acetate in hexanes) to 
afford 1.80 g of the title compound (72%) as a colorless oil.  This compounds characterization 
materials match the data provided in the following publication: Geherty, M. Catalytic 
Asymmetric Claisen Rearrangements. The Development of Ru(II)-Catalyzed Formal [3,3] 
Sigmatropic Rearrangements and Related Enolate Allylation Reactions. Ph.D. Thesis, University 
of Pittsburgh, December 2012.  
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1-Benzyl-3-((E)-3-(((E)-prop-1-en-1-yl)oxy)prop-1-en-1-yl)-1H-pyrrole 
(217): General procedure B was followed employing 180 mg of di(allyl) 
ether 211 (0.71 mmol), 3.18 mg of [Ir(COE)Cl]2  (3.5 mmol), 96 mg of 
PCy3 (0.21 mmol), and 79 mg of NaBPh4 (0.014 mmol) in 1.1 mL of CH2Cl2/ 0.2 mL 
Acetone.  The resulting product was utilized directly without purification to afford 121 g of the 
title compound (67%) as a light yellow oil. 
1
H NMR (400 MHz, CDCl3):  7.35-7.30 (m, 3H), 
7.11 (d, J = 8.5 Hz, 2H), 6.92 (t, J = 1.5 Hz, 1H), 6.17 (t, J = 2.0 Hz, 1H), 6.49 (d, J = 15.5 
Hz, 1H), 6.32 (t, J = 1.5 Hz, 1H), 6.24 (dd, J = 1.5, 11.0 Hz, 1H), 5.96 (dt, J = 6.5, 15.5 Hz, 
1H), 5.00 (s, 2H), 4.84 (m, 1H), 4.25 (dd, J =1, 5.5 Hz, 2H), 1.55 (d, J = 5.5 Hz, 3H). 
 
1-(Benzyloxy)-4-((E)-3-(((E)-prop-1-en-1-yl)oxy)prop-1-en-1-yl)benzene 
(218): General procedure B was followed employing 1.0 g of di(allyl) 
ether 212 (3.56 mmol), 16 mg of [Ir(COE)Cl]2  (0.017 mmol), 30 mg of PCy3 (0.11 mmol), 
and 24.5 mg of NaBPh4 (0.071 mmol) in 5.8 mL of CH2Cl2/ 0.2 mL Acetone.  The resulting 
product was utilized directly without further purification to afford 0.85 g of the title compound 
(85%) as a white solid. 
1
H NMR (400 MHz, CDCl3):  7.38-7.31 (m, 7H), 6.92 (d, J = 8.5 Hz, 
2H), 6.57 (d, J = 16.0 Hz, 1H), 6.27 (d, J = 16.0 Hz, 1H), 6.16 (dt, J = 6.5, 15.5 Hz, 1H), 5.07 (s, 
2H), 4.86 (m, 1H), 4.31 (d, J = 6.5 Hz, 2H), 1.56 (d, J = 5.0 Hz, 3H). 
 
rac-(2R,3S)-2-Methyl-3-phenylpent-4-enal (181): General procedure C was 
followed employing 2.8 g of allyl vinyl ether 180 (16 mmol) in 32 mL of toluene. 
The resulting product was utilized directly without further purification to afford 
2.8 g of the title compound (99%). This compounds characterization materials match the data 
 74 
provided in the following publication: Kerrigan, N. J.; Bungard, C. J.; Nelson, S. G. Tetrahedron 
2008, 64 (29), 6863-6869.  
 
 rac-(2R,3S)-3-(Furan-2-yl)-2-methylpent-4-enal (234): General procedure C 
was followed employing 519 mg of allyl vinyl ether 219 (3.16 mmol) in 7 mL of 
toluene. The resulting product was utilized directly without further purification to afford 490 
mg of the title compound (94%). This compounds characterization materials match the data 
provided in the following publication: Geherty, M. E.; Dura, R. D.; Nelson, S. G. J. Am. Chem. 
Soc. 2010, 132, 11875-11877. 
 
 rac-(2R,3S)-3-(3-Methoxyphenyl)-2-methylpent-4-enal (235): General 
procedure C was followed employing 1.95 g of allyl vinyl ether 220 (10 mmol) 
in 20 mL of toluene. The resulting product was utilized directly without further 
purification to afford 1.89 g of the title compound (97%). This compounds characterization 
materials match the data provided in the following publication: Geherty, M. E.; Dura, R. D.; 
Nelson, S. G. J. Am. Chem. Soc. 2010, 132, 11875-11877. 
 
 rac-(2R,3S)-3-(4-Bromophenyl)-2-methylpent-4-enal (236): General 
procedure C was followed employing 1.26 g of allyl vinyl ether 221 (5 mmol) 
in 10 mL of toluene. The resulting product was utilized directly without 
further purification to afford 1.16 g of the title compound (92%). This compounds 
characterization materials match the data provided in the following publication: Geherty, M. E.; 
Dura, R. D.; Nelson, S. G. J. Am. Chem. Soc. 2010, 132, 11875-11877. 
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rac-(2R,3S)-3-(1-Benzyl-1H-pyrrol-3-yl)-2-methylpent-4-enal (232): General 
procedure C was followed employing 40 mg of allyl vinyl ether 217 (0.15 mmol) 
in 5 mL of toluene. The resulting product was utilized directly without further 
purification to afford 35  mg of the title compound (87%). 
1
H NMR (300 MHz, CDCl3):   9.71 
(d, J = 2.5Hz, 1H), 7.38-7.28 (m, 3H), 7.10 (d, J = 6.0 Hz, 2H), 6.54 (t, J = 2.5 Hz, 1H), 6.50 (t, 
J = 2.0 Hz, 1H), 6.4 (d, J = 3.0 Hz, 1H), 5.99 (m, 1H), 5.13 (m, 2H), 5.02 (s, 2H), 3.61 (t, J = 
7.5 Hz, 1H), 2.70 (dt, J = 2.5, 4.5 Hz, 1H), 0.89 (d, J = 7.5 Hz, 3H). 
 
rac-(2R,3S)-3-(4-(Benzyloxy)phenyl)-2-methylpent-4-enal (233): General 
procedure C was followed employing 633 g of allyl vinyl ether 218 (2.25 
mmol) in 5 mL of toluene. The resulting product was utilized directly 
without further purification to afford 517 mg of the title compound (82%). 
1
H NMR (400 MHz, 
CDCl3):  9.70 (d, 3.0 Hz, 1H), 7.47-6.95 (m, 9H), 6.02(m, 1H), 5.11 (m, 2H), 5.05 (s, 2H), 
3.51 (t, J = 9.0 Hz, 1H), 2.76 (dt, J = 3.5, 7.0 Hz, 1H), 0.94 (d, J = 7.0 Hz, 3H). 
 
 rac-(2R,3S)-N-Benzyl-2-methyl-3-phenylpent-4-en-1-amine (185): General 
procedure D was followed employing 100 mg 181 (0.57 mmol), 242 mg of 
NaHB(OAc)3 (1.15 mmol), 0.125 mL of benzylamine (1.15 mmol), and 33 μL 
of acetic acid (0.57 mmol) in 6 mL of CH2Cl2. The crude product was purified 
by flash chromatography (50% diethyl ether in hexanes) to afford 99 mg of the title compound 
(65%) as a light yellow oil.  
1
H NMR (400 MHz, CDCl3):  7.33-7.15 (m, 10H), 6.06 (m, 1H), 
5.01 (m, 2H), 3.77 (d, J = 9.0 Hz, 2H), 3.14 (t, J = 9.0 Hz, , 1H), 2.76 (dd, J = 5.0, 7.0 Hz, 1H), 
2.45 (m,1H), 2.06 (m, 1H), 0.79 (d, J = 6.5 Hz, 3H); 
13
C NMR (100 MHz, CDCl3):  143.3, 
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141.0, 128.4,128.1, 127.5, 126.3, 115.0, 54.9, 54.2, 53.6, 37.9, 16.4; IR (thin film): 3061, 3026, 
2961, 2875, 2816,1492, 1452, 1117, 1072, 1028, 994, 913, 736 cm
-1
 ; HRMS (ESI) m/z calcd 
for C19H24N (M + H)
+ 
: 266.1909; found 266.1906. 
 
rac-(2R,3S)-N-Benzyl-3-(furan-2-yl)-2-methylpent-4-en-1-amine (234b): 
General procedure D was followed employing 490 mg of 234 (2.98 mmol),  1.26 
mg of NaHB(OAc)3 (5.96 mmol), 0.652 mL of benzylamine (5.96 mmol), and 
0.172 mL of acetic acid (2.98 mmol) in 30 mL of CH2Cl2. The crude product was 
purified by flash chromatography (60% diethyl ether in hexanes) to afford 600 mg of the title 
compound (79%) as a colorless oil.  
1
H NMR (400 MHz, CDCl3):  7.25-7.19 (m, 6H), 6.21 (t, J 
= 2.0 Hz, 1H), 5.89 (d, J = 3Hz, 1H), 5.88 (m, 1H), 5.04-5.00 (m, 2H), 3.68 (d, J = 3.5 Hz, 2H), 
3.40 (t, J = 7.5 Hz), 2.58 (dd, J = 5.0, 6.5 Hz, 1H), 2.36 (m, 1H), 2.03 (m, 1H), 0.81 (d, J = 
6.5 Hz, 3H); 
13
C NMR (100 MHz, CDCl3):  155.9, 140.8, 137.4, 128.1, 127.8, 126.6, 116.0, 
109.8, 105.7, 53.9, 52.9, 47.1, 37.02, 15.7; IR (thin film): 3063, 3030, 2973, 1640, 1557, 1500, 
1454, 1402, 1279, 1148, 1010, 922, 734 cm
-1
;  HRMS (ESI) m/z calcd for C17H22NO (M + H)
+ 
: 256.1701; found 256.1711. 
 
rac-(2R,3S)-N-Benzyl-3-(3-methoxyphenyl)-2-methylpent-4-en-1-amine 
(235b): General procedure D was followed employing 2.10 g  of 235 (10 
mmol),  4.2 g of NaHB(OAc)3 (20 mmol), 2.25 mL of benzylamine (20 mmol), 
and 0.590 mL of acetic acid (10 mmol) in 100 mL of CH2Cl2. The crude product 
was purified by flash chromatography (60% diethyl ether in hexanes) to afford 
2.01g of the title compound (65%) as a light yellow oil.  
1
H NMR (400 MHz, CDCl3):  7.33-
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7.20 (m, 7H), 6.74 (m, 2H), 6.00 (m, 1H), 5.02 (m, 2H), 3.78 (m, 5H), 3.10 (t, J = 8.0 Hz, 
1H), 2.77 (dd, J = 4.5, 7.0 Hz, 1H), 2.46 (m, 1H), 2.03 (m, 1H), 0.81 (d, J = 6.5 Hz, 3H); 
13
C 
NMR (100 MHz, CDCl3):  159.6, 145.1, 140.9, 129.3, 128.3, 128.0, 126.8, 120.4, 115.0, 
114.0, 111.1, 55.0,54.2, 53.6, 37.8, 16.4; IR (thin film): 3062, 3026, 2999, 2957, 2904, 2832, 
1600, 1584, 1489, 1453, 1316, 1262, 1161, 1117, 1047, 994, 913, 780, 735 cm
-1
; HRMS (ESI) 
m/z calcd for C20H25NO (M + H)
+ 
: 295.1936; found 295.1918. 
 
 rac-(2R,3S)-N-Benzyl-3-(4-bromophenyl)-2-methylpent-4-en-1-amine 
(236b): General procedure D was followed employing  1.0 g of 236 (3.95 
mmol),  1.67 g of NaHB(OAc)3 (8.0 mmol), 0.870 mL of benzylamine (8.0 
mmol), and  0.225 mL of acetic acid (4.0 mmol) in  40 mL of CH2Cl2. The 
crude product was purified by flash chromatography (60% ethyl acetate in 
hexanes) to afford 842 mg of the title compound (62%) as a colorless oil.  
1
H NMR (400 MHz, 
CDCl3):  7.34-6.95 (m, 9H), 5.89 (m, 1H), 4.97 (m, 2H), 3.68 (d, J= 3.5Hz, 2H), 3.09 (t, J = 
8.0 Hz, 1H), 2.64 (dd, J = 4.5, 7.0 Hz, 1H), 2.39 (m, 1H), 1.92 (m, 1H), 0.71 (d, J = 6.5 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3):  142.3, 140.4, 131.4, 129.9, 128.3, 128.2, 127.9, 119.8, 
115.5, 54.2, 53.9, 53.4, 37.8, 16.2; IR (thin film): 3063, 3026, 2961, 2874, 2816, 1637, 1487, 
1453, 1402, 1117, 1073, 1028, 1010, 915, 819, 736, 698 cm
-1
; HRMS (ESI) m/z calcd for 
C19H23NBr (M + H)
+ 
: 344.1014; found 344.1021. 
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rac-(2R,3S)-N-Benzyl-3-(4-(benzyloxy)phenyl)-2-methylpent-4-en-1-
amine (233b): General procedure D was followed employing 517 mg of 233 
(1.84 mmol), 778 g of NaHB(OAc)3 (3.68 mmol), 0.403 mL of benzylamine 
(3.68 mmol), and  0.105 mL of acetic acid (1.84 mmol) in 19 mL of CH2Cl2. 
The crude product was purified by flash chromatography (60% diethyl ether 
in hexanes) to afford 496 mg of the title compound (72%) as a colorless oil.
 1
H NMR (300 MHz, 
CDCl3):  7.45-6.91 (m, 14H), 5.56 (m, 1H), 5.04 (m, 4H), 3.81 (m, 2H), 3.13 (t, J = 8.5 Hz, 
1H), 2.76 (m, 1H), 2.46 (m, 1H), 2.04 (m, 1H), 0.82 (d, J = 6.5 Hz, 3H). 
 
rac-(3S,4R)-1-Benzyl-2-(iodomethyl)-4-methyl-3-phenylpyrrolidine (189): 
General procedure E was followed employing 2.0 g of pentamine 185 (7.53 
mmol), and1.86 g of  NIS (8.28 mmol) in 25 mL of THF. The resulting mixture 
was concentrated and immediately purified by flash chromatography (10% 
diethyl ether in hexanes) to afford 2.21 g of the title compound (75%) as a light yellow oil.  
1
H 
NMR (400 MHz, CDCl3):  7.27-7.05 (m, 10H), 4.29 (dt, 4.0, 7.0 Hz, 1H), 3.51 (d, J = 5 Hz, 
2H), 3.43 (dd, J = 3.0, 8.0 Hz, 1H), 2.93 (dd, J = 1.5, 6.5 Hz, 1H), 2.56 (t, J = 11 Hz, 1H), 2.31 
(t, J = 11 Hz, 1H), 1.94 (m, 1H), 1.86 (t, J = 11 Hz, 1H), 0.55 (d, 6.5 Hz, 3H); 
13
C NMR 
(100 MHz, CDCl3): 143.4, 137.6, 128.9, 128.3, 127.2, 126.9, 64.6, 62.0, 60.9, 60.5, 38.8, 
35.9, 18.1; IR (thin film): 3521, 2930, 2862, 1669, 1501, 1439, 1388, 1256, 1094, 1064 cm
-1
; 
HRMS (ESI) m/z calcd for C19H23NI (M + H)
+ 
: 392.0875; found 392.0877. 
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rac-(3R,4R)-1-Benzyl-3-(furan-2-yl)-2-(iodomethyl)-4-methylpyrrolidine 
(234c): General procedure E was followed employing 600 mg of pentamine 
234b (2.45 mmol), and 579 mg of NIS (2.58 mmol) in 7.5 mL of THF. The 
resulting mixture was concentrated and immediately purified by flash 
chromatography (10% diethyl ether in hexanes) to afford 521 mg of the title compound (58%) 
as a colorless oil.  
1
H NMR (400 MHz, CDCl3):  7.28-7.18 (m, 6H), 6.25 (m, 1H), 6.05 (d , J 
= 3.0 Hz, 1H), 4.37 (dt, J = 4.5, 10 Hz, 1H), 3.50 (d, J = 3.5 Hz, 2H), 3.40 (ddd, J = 2.0, 2.5, 
5.5 Hz, 1H), 2.90 (ddd, J = 2.0, 2.0, 6.0 Hz, 1H), 2.60 (q, J = 11 Hz, 2H), 2.03 (m, 1H), 1.81 
(t, J = 11.5 Hz, 1H), 0.65 (d, J = 6.5 Hz, 3H); 
13
C NMR (100 MHz, CDCl3):  155.7, 141.1, 
137.7, 128.9, 128.3, 127.2, 109.9, 107.1, 64.2, 61.8, 60.6, 54.0, 37.2, 32.2, 18.0; IR (thin 
film): 3027, 2954, 2926, 2872, 2801, 2758, 1495, 1454, 1126, 1009, 732 cm
-1
; HRMS (ESI) 
m/z calcd for C17H21NOI (M + H)
+ 
: 382.0668; found 382.0704. 
 
 rac-(3S, 4R) – 1 – Benzyl – 2 - ( iodomethyl ) – 3 - ( 3 – methoxyphenyl ) - 
4-methylpyrrolidine (235c): General procedure E was followed employing 
500 mg of pentamine 235b (1.69 mmol), and 417 mg of NIS (1.86 mmol) in 
5.6 mL of THF. The resulting mixture was concentrated and immediately 
purified by flash chromatography (10% diethyl ether in hexanes) to afford 361 
mg of the title compound (50%) as a light yellow oil.  
1
H NMR (400 MHz, CDCl3): 7.25-7.14 
(m, 6H), 6.73-6.62 (m, 3H), 4.27  (dt, J = 4.0, 7.0 Hz, 1H), 3.71 (s, 3H), 3.50 (d, J = 13 Hz, 
2H), 3.44 (ddd, J = 2.0, 2.0, 4.0 Hz, 1H), 2.92 (ddd, J = 2.0, 2.0, 6.0 Hz, 1H), 2.55 (t, J = 11 
Hz, 1H),  2.30 (t, J = 11 Hz, 1H), 1.96 (m, 1H), 1.92 (t, J = 11 Hz, 1H), 0.56 (d, J = 6.5 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3):  159.8, 159.6, 145.1, 137.7, 129.1, 128.4, 127.3, 112.0, 
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64.7, 62.0, 61.0, 60.6, 55.2, 38.8, 35.8, 18.2; IR (thin film): 3027, 2952, 2831, 2801, 2759, 
1601, 1585, 1491, 1454, 1435, 1365, 1317, 1264, 1155, 1046, 909, 876, 779, 734 cm
-1
; 
HRMS (ESI) m/z calcd for C20H25NOI (M + H)
+ 
: 422.0981; found 422.0952. 
 
rac - ( 3S, 4R ) -1 - Benzyl - 3 - ( 4 - bromophenyl ) - 2 - ( iodomethyl ) -4-
methylpyrrolidine (236c): General procedure E was followed employing 700 
mg of pentamine 236b (2 mmol), and 505 mg of NIS (2.2 mmol) in 7 mL of 
THF. The resulting mixture was concentrated and immediately purified by 
flash chromatography (10% diethyl ether in hexanes) to afford 517 mg of the title compound 
(55%) as a light yellow oil.   
1
H NMR (400 MHz, CDCl3): 7.39-6.95 (m, 6H), 4.21  (dt, J = 4.0, 
7.0 Hz, 1H), 3.5 (d, J = 13 Hz, 2H), 3.42 (ddd, J = 3.0, 9.0 Hz, 1H), 2.93 (appt d, J = 10 Hz, 
1H), 2.55 (t, J = 11 Hz, 1H),  2.30 (t, J = 11 Hz, 1H), 1.93 (m, 1H), 1.90 (t, J = 11 Hz, 1H), 
0.52 (d, J = 6.5 Hz, 3H); 
13
C NMR (100 MHz, CDCl3):  142.4, 137.6, 131.4, 128.9, 128.3, 
127.2, 120.6, 64.4. 61.8, 60.8, 60.0, 38.7, 35.2, 17.9; IR (thin film): 3026, 2953, 2802, 1491, 
1454, 1407, 1365, 1339, 1264, 1126, 1100, 1069, 1028, 1010, 877.6, 815, 738, 700 cm
-1
; HRMS 
(ESI) m/z calcd for C19H23NBrI (M + H)
+ 
: 471.0059; found 471.0052. 
 
rac-(3S,4R)-1-Benzyl-3-(4-(benzyloxy)phenyl)-2-(iodomethyl)-4-
methylpyrrolidine (233c): General procedure E was followed employing 
496 mg of pentamine 233b (1.33 mmol), and 329 mg of NIS (1.46 mmol) in 
4.5 mL of THF. The resulting mixture was concentrated and immediately 
purified by flash chromatography (10% diethyl ether in hexanes) to afford 325 mg of the title 
compound (48%) as a colorless oil.  
1
H NMR (300 MHz, CDCl3): 7.48-6.97 (m, 14H), 5.15 
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(s, 2H), 4.39 (dt. J = 4.0, 7.0 Hz, 1H), 3.65 (d, J = 13.5 Hz, 2H), 3.57 (m, 2H), 3.57 (m, 1H), 
3.04 (app d, J = 10 Hz, 1H), 2.69 (t, J = 11.5 Hz, 1H), 2.40 (t, J = 10.5 Hz, 1H), 2.09 (m, 1H), 
2.05 (m, 1H), 0.68 (t, J = 6.5 Hz, 3H). 
 
rac-(3S, 4R)-2-(Azidomethyl)-1-benzyl-4-methyl-3-phenylpyrrolidine 
(192): General procedure F was followed employing 360 mg of  pyrrolidine 
189 (0.920 mmol), and 90 mg of NaN3 (1.38 mmol) in 8 mL of DMF. The 
resulting product was purified by flash chromatography (10% ethyl acetate in 
hexanes) to afford 143 mg of the title compound 203 (51%) and 53 mg of compound 204 
(19%). 
1
H NMR (400 MHz, CDCl3):  7.27-7.14 (m, 10H), 3.53 (m, 1H), 3.50 (d, J = 4.5 
Hz, 2H), 3.11 (ddd, J = 4.0, 4.5, 6.5 Hz, 1H), 2.85 (ddd, J = 1.5, 2.0, 9.5 Hz, 1H), 2.00 (m, 
3H), 1.71 (t, J = 11 Hz, 1H), 0.58 (d, J = 6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): 140.7, 
137.7, 129.0, 128.6, 128.3, 128.1, 127.2, 127.1, 63.4, 62.6, 60.8, 58.0, 56.1, 36.0, 16.8; IR (thin 
film): 3061, 3028, 2952, 2905, 2804, 2762,  2097, 1494, 1453, 1367, 1346, 1264, 1109, 
1071, 1052, 754 cm
-1
; HRMS (ESI) m/z calculated for C19H23N4 (M + H)
+ 
: 307.1923; 
found 307.1921. 
 
rac- (3R, 4R) - 2 -(Azidomethyl)-1-benzyl-3-(furan-2-yl)-4-methylpyrrolidine 
(239): General procedure F was followed employing 521 mg of pyrrolidine 234c 
(1.36 mmol), and 133 mg of  NaN3 (2.05 mmol) in 11.5 mL of DMF. The 
resulting product was purified by flash chromatography (10% ethyl acetate in 
hexanes) to afford 138 mg of the title compound 239 (34%) and 136 mg of compound 239b 
(33%). 
1
H NMR (400 MHz, CDCl3):  7.31-7.17 (m, 6H), 6.27 (dd, J = 2.0, 1.0 Hz, 1H), 
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6.12 (d, J = 3.0 Hz, 1H), 3.66 (dt, J = 6.5, 4.5 Hz, 1H), 3.51 (d, J = 5.0 Hz, 2H), 3.08 (ddd, J 
= 1.0, 2.5, 5.0 Hz, 1H), 2.83 (ddd, J = 1.0, 2.5, 5.0 Hz, 1H), 2.14 (t, J = 11 Hz, 1H), 1.97 (m, 
1H), 1.86 (t, J = 11 Hz, 1H), 1.66 (t, J = 11 Hz, 1H), 0.67 (d, J = 6.5 Hz, 3H); 
13
C NMR (100 
MHz, CDCl3): 153.8, 141.5, 137.7, 129.0, 128.3, 127.2, 110.2, 107.8, 62.5, 61.8, 60.6, 57.6, 
49.3, 34.4, 16.9; IR (thin film): 3062, 3028, 2955, 2927, 2807, 2763, 2097, 1600, 1506, 1454, 1368, 
1348, 1265, 1148, 1109, 1069, 1052, 1028, 1010, 966, 918, 869, 803, 733, 699, 674, 598 cm
-1
; 
HRMS (ESI) m/z calculated for C17H21N4O (M + H)
+ 
: 297.1715; found 297.1710.  
 
rac - ( 3S, 4R) - 2 - ( Azidomethyl ) -1 - benzyl -3 - ( 3 -methoxyphenyl)-4-
methylpyrrolidine (240): General procedure F was followed employing 361 
mg of pyrrolidine 235c (0.857 mmol), and 83.5 mg of NaN3 (1.28 mmol) in 7 
mL of DMF. The resulting product was purified by flash chromatography 
(10% ethyl acetate in hexanes) to afford 132 mg of the title compound 240 
(46%) and 74 mg of compound 240b (26%). 
1
H NMR (400 MHz, CDCl3):  7.35-7.28 (m, 6H), 
6.84-6.78 (m, 3H), 3.81 (s, 3H), 3.63 (m, 1H), 3.59 (d, J = 5 Hz, 2H), 3.19 (ddd, J = 1.5, 3.0, 
4.5 Hz, 1H), 2.98 (ddd, J = 1.5, 2.0. 6 Hz, 1H), 2.04 (m, 3H), 1.80 (t, J = 11 Hz, 1H), 0.69 (d, 
J = 6.5 Hz, 3H); 
13
C NMR (100 MHz, CDCl3):  159.8, 142.4, 137.7, 129.6, 129.0, 128.4, 
128.3, 127.3, 112.2, 63.4, 62.7, 60.9, 57.9, 56.2, 55.1, 36.0, 16.8; IR (thin film): 3027, 2953, 
2804, 2763, 2096, 1601, 1585, 1491, 1454, 1436, 1368, 1264, 1155, 1109, 1049, 779, 744 
cm
-1
;  HRMS (ESI) m/z calculated for C20H25N4O (M + H)
+ 
: 337.2028; found 337.2036.  
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rac-(3S,4R)-2-(Azidomethyl)-1-benzyl-3-(4-bromophenyl)-4-
methylpyrrolidine (241): General procedure F was followed employing 
500 mg of pyrrolidine 236c (1.1 mmol),  and 104 mg of NaN3 (1.6 mmol) in 
9 mL of DMF. The resulting product was purified by flash chromatography 
(10% ethyl acetate in hexanes) to afford 178  mg of the title compound 241 (42%) and 116 mg 
of compound 241b (27%). 
1
H NMR (400 MHz, CDCl3):  7.46 (d, J = 9.5 Hz, 2H), 7.35-7.23 
(m, 5H), 7.10 (d, J = 8.0Hz, 2H), 3.59 (d, J = 3 Hz, 2H), 3.56-3.52 (m, 2H), 3.19 (ddd, J = 1.5, 
3.0, 5.0 Hz, 1H), 2.91 (ddd, J = 1.0, 2.5, 6.5 Hz, 1H), 2.02 (q, J = 11 Hz, 2H), 1.98 (m, 1H), 
1.78 (t, J = 11Hz, 1H), 0.61 (d, J = 6.5Hz, 3H); 
13
C NMR (100 MHz, CDCl3): 
 R 
(thin film): 3331, 3085, 3062, 3027, 2954, 2904, 2806, 2763, 2097, 1602, 1591, 1491, 1463, 
1454, 1407, 1368, 1346, 1307, 1265, 1185, 1131, 1110, 1071, 1053, 1028, 1010, 965, 909, 871, 
815, 734, 700, 648, 617, 541 cm
-1
; HRMS (ESI) m/z calculated for C19H22N4Br (M + H)
+ 
: 
385.1028; found 385.1020. 
 
rac-(3S,4R)-2-(Azidomethyl)-1-benzyl-3-(4-(benzyloxy)phenyl)-4-
methylpyrrolidine (238):
 
General procedure F was followed employing 325 
mg of pyrrolidine 233c (0.653 mmol),  and 63.7 mg of NaN3 (0.980 mmol) 
in 5.5 mL of DMF. The resulting product was purified by flash 
chromatography (10% ethyl acetate in hexanes) to afford 123 mg of the title compound 238 
(46%) and 94 mg of compound 238b (34%). 
1
H NMR (300 MHz, CDCl3):  7.45-6.94 (m, 
14H), 5.08 (s, 2H), 3.59 (m, 3H), 3.22 (m, 1H), 2.93 (m, 1H), 2.05 (m, 3H), 1.84 (t, J = 11 Hz, 
1H), 0.67 (d, J = 6.0 Hz, 3H). 
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rac-(4S,5R)-3-Azido-1-benzyl-5-methyl-4-phenylpiperidine (193):
 1
H NMR 
(400 MHz, CDCl3):  7.40-7.22 (m, 10H), 4.14 (d, J = 13.5 Hz, 1H), 3.58  (d, J 
=13.5 Hz, 1H), 3.48 (dd, J = 3.0, 9.5 Hz, 1H), 2.97 (m, 2H), 2.79 (m, 3H), 2.31 
(m, 1H), 0.96 (d, J = 6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): 
128.7, 128.6, 128.4, 128.2, 127.0, 126.9, 72.6, 60.6, 59.4, 56.4, 
51.0, 39.5, 18.0; IR (thin film): 3084, 3062, 3028, 3003, 2957, 2923, 2869, 2796, 2729, 2097, 
1724, 1703, 1601, 1584, 1494, 1452, 1373, 1357, 1335, 1286, 1203, 1137, 1071, 1029, 991, 
959, 915, 827, 755, 700, 649 cm
-1
; HRMS (ESI) m/z calculated for C19H23N4 (M + H)
 +
: 
307.1923; found 307.1916. 
 
rac-(4R,5R)-3-Azido-1-benzyl-4-(furan-2-yl)-5-methylpiperidine (239b):
 1
H 
NMR (400 MHz, CDCl3):  7.29-7.15 (m, 6H), 6.22 (dd, J = 1.5, 2.0 Hz, 1H), 
6.00 (d, J = 3.0 Hz, 1H), 4.00 (d, J =  13 Hz, 1H), 3.42 (dd, J = 5.0, 10.0 Hz, 
1H), 3.38 (d, J = 13 Hz, 1H), 3.03 (dd, J = 3.5 Hz, 10 Hz, 1H), 2.91 (m, 1H), 
2.88 (t, J = 9.0 Hz, 1H), 2.63, (d, J = 9.0 Hz, 2H), 2.28 (m, 1H), 0.98 (d, J = 4 
Hz, 3H); 
13
C NMR (100 MHz, CDCl3): 155.0, 141.5, 139.2, 128.4, 128.2, 127.0, 110.0, 105.7, 
69.5, 60.0, 59.1, 51.3, 49.0, 36.4, 18.4; IR (thin film): 3028, 2959, 2925, 2870, 2798, 2098, 
1596, 1506, 1496, 1452, 1376, 1333, 1290, 1239, 1147, 1070, 1011, 911, 803, 734  cm
-1
; 
HRMS (ESI) m/z calcd for C17H21N4O (M + H)
+ 
: 297.1715; found 297.1711. 
 
rac-(4S,5R)-3-Azido-1-benzyl-4-(3-methoxyphenyl)-5-methylpiperidine 
(240b):
 1
H NMR (400 MHz, CDCl3):  7.32-7.14 (m, 6H), 6.75-6.69 (m, 3H), 
4.03 (d, J = 11, 5.0 Hz, 1H), 3.73 (s, 3H), 3.44 (d, J = 11.5 Hz, 1H), 3.37 (dd, 
J = 3.0, 10.0 Hz, 1H),  2.93 (dd, J = 3.0, 10.0 Hz, 1H), 2.86 (td, J = 3.0 , 13 
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Hz, 1H), 2.69 (m, 3H), 2.21 (m, 1H), 0.88 (d, J = 7.0 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3):  159.7, 142.9, 139.4, 129.6, 128.5, 128.2, 126.9, 120.4, 114.0, 111.6, 72.3, 60.4, 
59.2, 56.2, 55.1, 51.0, 39.3, 18.0; IR (thin film): 3027, 2956, 2923, 2868, 2834, 2794, 2097, 
1601, 1584, 1491, 1453, 1373, 1285, 1266, 1159, 1047, 777, 738 cm
-1
; HRMS (ESI) m/z calcd 
for C20H25N4O (M + H)
+ 
: 337.2028; found 337.2013. 
 
rac-(4S,5R)-3-Azido-1-benzyl-4-(4-bromophenyl)-5-methylpiperidine 
(241b):
 1
H NMR (400 MHz, CDCl3):  7.44 (d, J = 8.5 Hz, 2H), 7.38-7.34 (m, 
5H), 7.10 (d, J = 8.5 Hz, 2H), 4.11 (d, J = 13 Hz, 1H), 3.52 (d, J = 3.0 Hz, 1H), 
3.45 (dd, J = 3.0, 10.0 Hz, 1H), 3.00 (dd, 3.0, 10.0 Hz, 1H), 2.90 (m, 1H), 2.78 
(dd, J = 2.5, 6.0 Hz, 2H), 2.76 ( t, J = 10 Hz, 1H), 2.24 (m, 1H), 0.98 (d, J = 7.0 
Hz, 3H);
 13
C NMR (100 MHz, CDCl3):  140.2, 139.2, 131.7, 129.8, 128.5, 128.3, 126.9, 120.5, 
72.3, 60.3, 59.1, 55.7, 50.8, 39.4, 17.7; IR (thin film): 3027, 2957, 2924, 2797, 2097, 1489, 1452, 
1410, 1283, 1136, 1073, 1010, 910, 816, 737, 699; HRMS (ESI) m/z calcd for C19H22N4Br (M 
+ H)
+ 
: 385.1028; found 385.1036. 
 
rac-(4S,5R)-3-Azido-1-benzyl-4-(4-(benzyloxy)phenyl)-5-methylpiperidine 
(238b): 
1
H NMR (400 MHz, CDCl3): 7.33-6.81 (m, 14H), 4.92 (s, 2H), 3.98 (d, 
J = 13 Hz, 1H), 3.39 (d, J = 13.5 Hz, 1H), 3.30 (dd, J = 3.0, 10 Hz, 1H), 2.85 
(dd, J = 3.0, 10.0 Hz, 1H), 2.77 (m, 1H), 2.63 (d, J = 7.5 Hz, 2H), 2.60 (t, J = 
10.0 Hz, 1H), 2.12 (m, 1H), 0.81 (d, J = 7.0 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3):  157.7, 139.5, 137.1.133.4, 129.2, 129.1, 128.6, 128.6, 128.4, 128.3, 128.0, 127.6, 
127.5, 127.0, 115.0, 72.5, 70.0, 60.4, 59.3, 55.5, 51.0, 39.3, 17.8. 
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rac-((3S,4R)-4-Methyl-3-phenylpyrrolidin-2-yl)methanamine (196): General 
procedure G was followed employing 1.03 g of pyrrolidine 192 (3.38 mmol), 
473 mg of Pd(OH)2/C (0.338 mmol),  and 2.66 g of NH4HCO2 (42.3 mmol) in 
35 mL of EtOH. The resulting oil was utilized directly without any further purification to yield 
578 mg of the title compound (90%). 
1
H NMR (400 MHz, CDCl3):  7.32-7.18 (m, 5H), 3.23 
(dd, J = 1.0, 3.5 Hz, 1H), 3.08 (dd, J = 1.0, 3.5 Hz, 1H), 2.92 (dt, J = 4.5, 10 Hz, 1H), 2.44 
(t, J = 10.5 Hz, 1H), 2.36 (t, J = 10.5 Hz, 1H), 1.89 (t, J = 11.0 Hz, 1H), 1.79 (m, 1H), 1.49, 
(broad s, 3H), 0.59 (d, J = 6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): 141.7, 128.6, 126.7, 
60.2, 54.5, 54.4, 54.3, 37.4, 17.0; IR (thin film): 3027, 2954, 2922, 2867, 2795, 2360, 2339, 
1493, 1453, 753 cm
-1
; HRMS (ESI) m/z calculated for C12H18N2 (M)
+ 
: 190.146999; found 
190.146829. 
 
rac-((3R,4R)-3-(Furan-2-yl)-4-methylpyrrolidin-2-yl)methanamine (244): 
General procedure G was followed employing 136 mg of pyrrolidine 239 (0.459 
mmol), 64 mg of Pd(OH)2/C (0.045 mmol), and 361 mg of NH4HCO2 (5.73 
mmol) in 5 mL of EtOH . The resulting oil was utilized directly without any further 
purification to yield 75 mg of the title compound (91%). 
1
H NMR (400 MHz, MeOD):  7.47 
(appt s, 1H), 6.39 (dd, J = 2.0, 3.0 Hz, 1H), 6.23(d, J = 3.0 Hz, 1H),  3.19 (dd, J = 5.0, 
8.5 Hz, 1H), 3.04 (dd, J = 5.0, 8.5 Hz, 1H), 2.94 (dt, J = 4.0, 6.0 Hz, 1H), 2.36 (t, J = 11 Hz, 
1H), 2.27 (t, J = 11.0 Hz, 1H), 2.18 (t, J = 10.5 Hz, 1H), 1.94 (m, 1H), 0.71 (d, J = 7.0 Hz, 3H); 
13
C NMR (100 MHz, MeOD): 154.4, 141.6, 109.7, 107.4, 52.7, 52.0, 51.9, 51.4, 35.0, 
15.8; IR (thin film): 3849, 3741, 3583, 3365, 2298, 1588, 1468 cm
-1
; HRMS (ESI) m/z 
calculated for C10H17N2 O (M)
+ 
: 181.13354; found 181.13308. 
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rac- ( ( 3S, 4R)-3-(3-Methoxyphenyl)-4-methylpyrrolidin-2-yl) methanamine 
(245): General procedure G was followed employing 132 mg of pyrrolidine 240 
(0.392 mmol), 55 mg of Pd(OH)2/C (0.039 mmol), and 308 mg of NH4HCO2 
(4.90 mmol) in 4 mL of EtOH. The resulting oil was utilized directly without any 
further purification to yield 79 mg of the title compound (93%). 
1
H NMR (400 MHz, CDCl3):  
1
H NMR (400 MHz, MeOD):  7.29-723 (m, 1H), 6.84-6.81 (m, 3H), 3.72 (s, 3H), 3.58 (m, 
1H), 3.33 (dd, J = 3.5, 9.0 Hz, 1H), 2.98 (t, J = 11.5 Hz, 1H), 2.72 (t,  J = 12.5 Hz, 1H), 2.42 
(t, J = 11.0 Hz, 1H), 2.14 (m, 2H), 0.65 (d, J = 6.0 Hz, 3H); 
13
C NMR (100 MHz, MeOD): 
 138.8, 130.2, 129.2, 128.1, 127.3, 113.3, 54.4, 53.1, 50.2, 49.7, 46.4, 33.9, 15.0; IR (thin 
film): 3904.1, 3871.7, 3854.1, 3854.1, 3840.3, 3821.8, 3806.8, 3751.4, 3735.7, 3712.2, 3690.3, 
3676.4, 3649.5, 3629.7, 3399.7, 1647.7, 1387.7, 1324.9, 1064.7 cm
-1
; HRMS (ESI) m/z 
calculated for C13H21N2 O (M)
+ 
: 221.16484; found 221.16457. 
 
rac- (3S,4R)-1-Benzyl-3-methyl-4-phenyl-1-azoniabicyclo[3.1.0]hexane 
hexafluoroantimonate (V) (194): To a rt solution of pyrrolidine  189 (130 
mg, 0.332 mmol) in CH2Cl2 (11 mL) was added Silver hexafluoroantimonate 
(V) (1.2 equiv, 114 mg, 0.398 mmol) in the dark.   The resulting mixture 
was stirred 2 h at rt, then filtered through a pad of Celite
®
. The resulting solid was 
recrystallized with CH2Cl2/Hexanes to afford 157 mg of the title compound (95%) as a 
colorless solid. Recrystallization of 194 from Et2O/Hexanes yielded crystals suitable for X-ray 
diffraction analysis (Appendix B). mp 38-42 °C; 
1
H NMR (400 MHz, CDCl3):  7.57-7.02 
(m, 10H), 4.80 (d, J = 13.5 Hz, 1H), 4.32 (d, J = 13.5 Hz, 1H), 4.09 (m, 1H), 3.77 (m, 1H), 
3.62 (m, 1H), 3.36 (m, 2H), 3.08 (dd, J = 3.0, 5.0 Hz, 1H), 2.57 (m, 1H), 1.01 (d, J = 7 Hz, 
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3H); 
13
C NMR (100 MHz, CDCl3):  137.6, 131.1, 131.0, 129.9, 129.4, 128.6, 128.2, 
127.1, 64.0, 62.8, 58.5, 54.2, 51.7, 48.2, 16.48; IR (thin film): 3054, 2986, 2305, 2253, 1421, 
1265, 909, 738, 704, 661 cm
-1
; HRMS (ESI) m/z calculated for C19H22N (M)
+ 
: 264.1752; 
found 264.1745. 
 
N-((1R,2S)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl)-4-(pyrrolidin-1-
yl)picolinamide (249): This compound was prepared according to literature 
procedure and matches the characterization data provided in the following 
the publication: Geherty, M.E.; Dura, R.D.; Nelson, S.G. J. Am. Chem. Soc. 
2010, 132, 11875-11877. 
 
(2R, 3R)-2-Methyl-3-phenylpent-4-enal (250): [CpRu(CH3CN)3]PF6 (5 mol %, 
31 mg, 0.07 mmol), picolinamide 249 (5 mol %, 23 mg, 0.07 mmol) and THF (2.9 
mL) were combined in a nitrogen-filled glovebox. The mixture was periodically agitated over 30 
min, then transferred to a mixture containing allyl vinyl ether (250 mg, 1.43 mmol), 4Å MS 
(100% wt/wt, 250 mg) and B(OPh)3 (5 mol %, 21 mg, 0.07 mmol). Immediately after removal 
from the glovebox, CH3CN (20 mol %, 15 µL, 0.3 mmol) was added and the resulting solution 
was stirred an additional 24 hours at ambient temperature. The resultant solution was 
concentrated under a stream of N2, filtered through a plug of Florisil
®
 and concentrated to yield 
225 mg (90%) as a mixture of 250 and (E)-2-methyl-5-phenylpent-4-enal as the only detectable 
products. Separating the stereoisomers of  250 by GLC flow rate 1.0 mL/min, method: 90 °C for 
10 min, ramp @ 0.7 °C/min to 160 °C, hold for 5 min; Tr (min) = 44.9 [(2S, 3S)-250anti], 45.6 
(250syn1), 46.9 (250syn2), 47.4 [(2R, 3R)-250anti] (ratio = 17.6:11.5:31.8:431) provided the 
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enantiomer ratio (2S, 3S)-250anti: (2R,3R)-250anti = 3.9:96.1 (92% ee).  
1
H NMR (400 MHz, 
CDCl3):   9.57 (d, J = 3 Hz, 1H), 7.35-7.22 (m, 5H), 5.99 (m, 1H), 5.15 (d, J = 6.0 Hz, 1H), 
3.61 (t, J = 9 Hz, 1H), 2.83 (m, 1H), 1.15 (d, J = 7 Hz). This compound was prepared according 
to literature procedure and matches the characterization data provided in the following the 
publication: Geherty, M.E.; Dura, R.D.; Nelson, S.G. J. Am. Chem. Soc. 2010, 132, 11875-
11877. 
 
(2R,3R)-N-Benzyl-2-methyl-3-phenylpent-4-en-1-amine (252): General 
procedure D was followed employing 200 mg of aldehyde 250 (1.14 mmol),  
480 mg of NaHB(OAc)3 (2.3 mmol), 0.25 mL of benzylamine  (2.3 mmol), and 
66 µL of acetic acid (1.14 mmol) in 12 mL of CH2Cl2. The crude product was 
purified by flash chromatography (70% diethyl ether in hexanes) to afford 181 mg of the title 
compound (60%) as a colorless oil. [α]
23
D  
+ 38 (c 2.0, CHCl3);  
1
H NMR (400 MHz, CDCl3):  
7.31-7.17 (m, 10H), 6.01 (m, 1H), 5.04 (m,2H), 3.65 (d, J = 11.0 Hz, 2H), 3.19 (t, J = 9.0 Hz, , 
1H), 2.52 (dd, J = 5.0, 7.0 Hz, 1H), 2.33 (dd, J = 4.5, 7.0 Hz,  1H), 2.05 (m, 1H), 0.98 (d, J = 6.5 
Hz, 3H); 
13
C NMR (100 MHz, CDCl3): δ 143.9, 139.9, 128.4, 128.3, 128.0, 127.8, 126.8, 126.1, 
115.7, 54.4, 54.0, 53.7, 38.0, 16.0; IR (thin film): 3835, 3027, 2959, 2926, 1638, 1493, 1453, 
1116, 912, 735, 699 cm
-1
 ; HRMS (ESI) m/z calcd for C19H24N (M + H)
+ 
: 266.1909; found 
266.1904.  
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(2S,3R,4R)-1-Benzyl-2-(iodomethyl)-4-methyl-3-phenylpyrrolidine (253): 
General procedure E was followed employing 150 mg of pentamine 252 (0.57 
mmol), and 140 mg of NIS (0.63 mmol) in 2 mL of THF. The resulting mixture 
was purified by flash chromatography (10% diethyl ether in hexanes) to afford 
63 mg of an inseparable mixture of the title compound 253, and 1-benzyl-3-iodo-5-methyl-4-
phenylpiperidine as a light yellow oil. 
1
H NMR (400 MHz, CDCl3):  7.40-7.10 (m, 10H), 4.67 
(dt, 4.5, 7.0 Hz, 1H), 3.55 (d, J = 5 Hz, 2H), 3.25 (dd, J = 3.0, 7.0 Hz, 1H), 3.12 (dd, J = 4.5, 
8.0 Hz, 1H), 2.87 (m, 3H), 2.02 (m, 1H), 0.54 (d, 7.0 Hz, 3H). 
 
1 
Characterization data obtained for 
1
H NMR only. Compound not utilized in final route.   
2 
Characterization data obtained for 
1
H and 
13
C NMR only. Compound not utilized in final route.   
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APPENDIX A 
X-RAY CRYSTAL DATA FOR (S,E)-6-METHYL-8-((1-(TRIISOPROPYLSILYL)-1H-
PYRROL-2-YL)METHYLENE)-6,7,8,9-TETRAHYDRO-5H-PYRROLO[1,2-A]AZEPIN-
5-ONE 89 
 
Figure 14. X-ray crystal structure of 89 
 
 
ORTEP structure of (S,E)-6-methyl-8-((1-(triisopropylsilyl)-1H-pyrrol-2-yl)methylene)-6,7,8,9-
tetrahydro-5H-pyrrolo[1,2-a]azepin-5-one. The molecular structure is drawn with 50% 
probability displacement ellipsoids; hydrogen atoms are drawn with an artificial radius.  
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Table 7. Crystallographic Information for Compound 89 
Identification code perez1 
Chemical formula C24H36N2OSi 
Formula weight 396.64 
Temperature 100(2) K 
Wavelength 1.54178 Å 
Crystal size 0.020 x 0.140 x 0.200 mm 
Crystal habit clear green plate 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 7.3821(3) Å α = 100.975(3)° 
 
b = 11.1160(5) Å β = 99.125(2)° 
 
c = 15.2794(7) Å γ = 108.084(2)° 
Volume 1137.81(9) Å
3
 
 
Z 2 
Density (calculated) 1.158 g/cm
3
 
Absorption coefficient 1.020 mm
-1
 
F(000) 432 
 
Table 8. Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) for 89 
 
x/a y/b z/c U(eq) 
Si1 0.05288(6) 0.20810(4) 0.86395(3) 0.01729(19) 
O1 0.77490(18) 0.40359(14) 0.61921(9) 0.0283(3) 
C1 0.7814(3) 0.16723(17) 0.85265(13) 0.0204(4) 
N1 0.0849(2) 0.08457(14) 0.77980(10) 0.0193(3) 
N2 0.5123(2) 0.46806(14) 0.61705(10) 0.0189(3) 
C2 0.6719(3) 0.1662(2) 0.75851(14) 0.0294(5) 
C3 0.6899(3) 0.03516(19) 0.87475(15) 0.0292(5) 
C4 0.1625(3) 0.18985(17) 0.97931(12) 0.0206(4) 
C5 0.3854(3) 0.2208(2) 0.99879(14) 0.0284(5) 
C6 0.1096(3) 0.2684(2) 0.05917(13) 0.0294(5) 
C7 0.1692(3) 0.37321(18) 0.84274(15) 0.0299(5) 
C8 0.3838(3) 0.40516(18) 0.83567(13) 0.0262(4) 
C9 0.1370(4) 0.4826(2) 0.90539(19) 0.0451(6) 
C10 0.1033(3) 0.97052(17) 0.79822(13) 0.0218(4) 
C11 0.1175(3) 0.89215(17) 0.72201(14) 0.0236(4) 
C12 0.1077(3) 0.95680(17) 0.65140(13) 0.0210(4) 
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x/a y/b z/c U(eq) 
C13 0.0873(2) 0.07420(16) 0.68731(12) 0.0179(4) 
C14 0.0714(2) 0.17646(17) 0.64175(12) 0.0185(4) 
C15 0.1710(2) 0.21673(16) 0.58035(12) 0.0173(4) 
C16 0.1498(2) 0.33110(17) 0.54477(12) 0.0188(4) 
C17 0.3135(2) 0.45528(17) 0.59844(12) 0.0186(4) 
C18 0.3008(3) 0.56714(18) 0.64568(13) 0.0237(4) 
C19 0.4937(3) 0.65324(18) 0.69464(14) 0.0271(4) 
C20 0.6195(3) 0.59132(18) 0.67709(13) 0.0239(4) 
C21 0.6025(3) 0.37823(17) 0.58713(12) 0.0199(4) 
C22 0.4768(2) 0.25459(17) 0.51322(12) 0.0191(4) 
C23 0.3167(2) 0.16149(17) 0.54753(12) 0.0183(4) 
C24 0.6033(3) 0.18226(18) 0.47554(13) 0.0234(4) 
 
Table 9. Bond lengths [Å] and angles [°] for 89 
Si1-N1 1.7947(16) Si1-C7 1.8834(19) 
Si1-C1 1.8833(18) Si1-C4 1.8944(18) 
O1-C21 1.211(2) C1-C2 1.531(2) 
C1-C3 1.540(2) C1-H1A 1.0 
N1-C10 1.391(2) N1-C13 1.399(2) 
N2-C20 1.401(2) N2-C17 1.406(2) 
N2-C21 1.409(2) C2-H2A 0.98 
C2-H2B 0.98 C2-H2C 0.98 
C3-H3A 0.98 C3-H3B 0.98 
C3-H3C 0.98 C4-C5 1.539(2) 
C4-C6 1.536(3) C4-H4A 1.0 
C5-H5A 0.98 C5-H5B 0.98 
C5-H5C 0.98 C6-H6A 0.98 
C6-H6B 0.98 C6-H6C 0.98 
C7-C9 1.504(3) C7-C8 1.539(3) 
C7-H7A 1.0 C8-H8A 0.98 
C8-H8B 0.98 C8-H8C 0.98 
C9-H9A 0.98 C9-H9B 0.98 
C9-H9C 0.98 C10-C11 1.355(3) 
C10-H10 0.86(2) C11-C12 1.410(3) 
C11-H11 0.92(3) C12-C13 1.379(3) 
C12-H12 0.96(2) C13-C14 1.466(2) 
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C14-C15 1.340(3) C14-H14 0.94(2) 
C15-C23 1.500(2) C15-C16 1.515(2) 
C16-C17 1.502(2) C16-H16A 1.00(2) 
C16-H16B 0.96(2) C17-C18 1.352(3) 
C18-C19 1.431(3) C18-H18 0.96(2) 
C19-C20 1.347(3) C19-H19 0.92(3) 
C20-H20 0.96(3) C21-C22 1.520(2) 
C22-C24 1.520(2) C22-C23 1.545(2) 
C22-H22 1.00(2) C23-H23A 0.96(2) 
C23-H23B 0.95(2) C24-H24A 0.98 
C24-H24B 0.98 C24-H24C 0.98 
N1-Si1-C7 109.31(8) N1-Si1-C1 107.35(8) 
C7-Si1-C1 111.20(8) N1-Si1-C4 105.81(8) 
C7-Si1-C4 114.55(9) C1-Si1-C4 108.26(8) 
C2-C1-C3 109.99(16) C2-C1-Si1 113.49(13) 
C3-C1-Si1 110.69(12) C2-C1-H1A 107.5 
C3-C1-H1A 107.5 Si1-C1-H1A 107.5 
C10-N1-C13 106.19(15) C10-N1-Si1 122.52(13) 
C13-N1-Si1 131.21(12) C20-N2-C17 108.04(15) 
C20-N2-C21 121.93(15) C17-N2-C21 130.00(15) 
C1-C2-H2A 109.5 C1-C2-H2B 109.5 
H2A-C2-H2B 109.5 C1-C2-H2C 109.5 
H2A-C2-H2C 109.5 H2B-C2-H2C 109.5 
C1-C3-H3A 109.5 C1-C3-H3B 109.5 
H3A-C3-H3B 109.5 C1-C3-H3C 109.5 
H3A-C3-H3C 109.5 H3B-C3-H3C 109.5 
C5-C4-C6 110.11(15) C5-C4-Si1 114.34(13) 
C6-C4-Si1 112.65(12) C5-C4-H4A 106.4 
C6-C4-H4A 106.4 Si1-C4-H4A 106.4 
C4-C5-H5A 109.5 C4-C5-H5B 109.5 
H5A-C5-H5B 109.5 C4-C5-H5C 109.5 
H5A-C5-H5C 109.5 H5B-C5-H5C 109.5 
C4-C6-H6A 109.5 C4-C6-H6B 109.5 
H6A-C6-H6B 109.5 C4-C6-H6C 109.5 
H6A-C6-H6C 109.5 H6B-C6-H6C 109.5 
C9-C7-C8 113.02(18) C9-C7-Si1 113.46(15) 
C8-C7-Si1 114.58(13) C9-C7-H7A 104.8 
C8-C7-H7A 104.8 Si1-C7-H7A 104.8 
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C7-C8-H8A 109.5 C7-C8-H8B 109.5 
H8A-C8-H8B 109.5 C7-C8-H8C 109.5 
H8A-C8-H8C 109.5 H8B-C8-H8C 109.5 
C7-C9-H9A 109.5 C7-C9-H9B 109.5 
H9A-C9-H9B 109.5 C7-C9-H9C 109.5 
H9A-C9-H9C 109.5 H9B-C9-H9C 109.5 
C11-C10-N1 110.33(17) C11-C10-H10 125.1(14) 
N1-C10-H10 124.4(14) C10-C11-C12 107.20(16) 
C10-C11-H11 129.3(16) C12-C11-H11 123.5(17) 
C13-C12-C11 107.75(17) C13-C12-H12 125.3(13) 
C11-C12-H12 126.9(13) C12-C13-N1 108.53(15) 
C12-C13-C14 128.83(17) N1-C13-C14 122.64(15) 
C15-C14-C13 126.13(16) C15-C14-H14 116.6(12) 
C13-C14-H14 117.2(12) C14-C15-C23 124.17(16) 
C14-C15-C16 119.82(16) C23-C15-C16 115.88(15) 
C17-C16-C15 110.02(14) C17-C16-H16A 104.2(11) 
C15-C16-H16A 112.6(11) C17-C16-H16B 112.5(14) 
C15-C16-H16B 116.1(14) H16A-C16-H16B 100.5(17) 
C18-C17-N2 107.41(15) C18-C17-C16 128.28(16) 
N2-C17-C16 123.91(15) C17-C18-C19 108.51(17) 
C17-C18-H18 126.3(15) C19-C18-H18 124.9(15) 
C20-C19-C18 107.80(17) C20-C19-H19 125.5(15) 
C18-C19-H19 126.6(15) C19-C20-N2 108.25(17) 
C19-C20-H20 131.8(14) N2-C20-H20 119.9(14) 
O1-C21-N2 119.36(16) O1-C21-C22 123.24(17) 
N2-C21-C22 117.39(15) C24-C22-C21 110.65(15) 
C24-C22-C23 109.58(14) C21-C22-C23 112.66(15) 
C24-C22-H22 110.2(11) C21-C22-H22 106.1(12) 
C23-C22-H22 107.5(12) C15-C23-C22 115.55(14) 
C15-C23-H23A 109.3(12) C22-C23-H23A 106.1(12) 
C15-C23-H23B 110.0(13) C22-C23-H23B 109.8(13) 
H23A-C23-H23B 105.5(16) C22-C24-H24A 109.5 
C22-C24-H24B 109.5 H24A-C24-H24B 109.5 
C22-C24-H24C 109.5 H24A-C24-H24C 109.5 
H24B-C24-H24C 109.5 
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Table 10. Anisotropic atomic displacement parameters (Å
2
) for 89 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k 
a
*
 b
*
 U12 ] 
U11 U22 U33 U23 U13 U12 
Si1 0.0165(3) 0.0150(3) 0.0192(3) 0.0037(2) 0.0039(2) 0.0045(2) 
O1 0.0158(7) 0.0358(8) 0.0295(7) 0.0043(6) 0.0013(5) 0.0082(6) 
C1 0.0188(9) 0.0210(9) 0.0223(9) 0.0056(7) 0.0052(7) 0.0080(7) 
N1 0.0172(7) 0.0175(7) 0.0228(8) 0.0049(6) 0.0045(6) 0.0058(6) 
N2 0.0162(7) 0.0200(7) 0.0172(7) 0.0025(6) 0.0015(6) 0.0042(6) 
C2 0.0190(9) 0.0413(11) 0.0270(10) 0.0085(9) 0.0026(7) 0.0109(8) 
C3 0.0191(9) 0.0249(10) 0.0424(12) 0.0118(9) 0.0066(8) 0.0043(7) 
C4 0.0196(9) 0.0190(8) 0.0200(9) 0.0037(7) 0.0019(7) 0.0046(7) 
C5 0.0194(10) 0.0295(10) 0.0309(11) 0.0101(9) -0.0011(8) 0.0033(8) 
C6 0.0324(11) 0.0324(10) 0.0215(10) 0.0062(8) 0.0044(8) 0.0102(9) 
C7 0.0316(11) 0.0207(9) 0.0412(12) 0.0101(9) 0.0171(9) 0.0088(8) 
C8 0.0246(10) 0.0219(9) 0.0272(10) 0.0072(8) 0.0058(8) 0.0009(7) 
C9 0.0479(14) 0.0277(11) 0.0569(15) 0.0069(11) 0.0166(12) 0.0097(10) 
C10 0.0223(9) 0.0183(9) 0.0252(10) 0.0081(8) 0.0053(7) 0.0065(7) 
C11 0.0214(9) 0.0160(9) 0.0326(11) 0.0051(8) 0.0049(7) 0.0069(7) 
C12 0.0159(9) 0.0195(8) 0.0244(10) 0.0015(7) 0.0040(7) 0.0046(7) 
C13 0.0128(8) 0.0184(8) 0.0190(8) 0.0016(7) 0.0023(6) 0.0033(6) 
C14 0.0147(8) 0.0185(8) 0.0205(9) 0.0013(7) 0.0015(7) 0.0069(7) 
C15 0.0135(8) 0.0170(8) 0.0169(8) 0.0000(7) -0.0017(6) 0.0043(6) 
C16 0.0153(9) 0.0218(9) 0.0197(9) 0.0047(7) 0.0025(7) 0.0081(7) 
C17 0.0177(9) 0.0197(8) 0.0196(9) 0.0074(7) 0.0045(7) 0.0067(7) 
C18 0.0292(10) 0.0225(9) 0.0232(10) 0.0072(8) 0.0089(8) 0.0120(8) 
C19 0.0373(11) 0.0173(9) 0.0241(10) 0.0025(8) 0.0074(8) 0.0073(8) 
C20 0.0236(10) 0.0203(9) 0.0205(9) 0.0033(7) 0.0016(7) 0.0006(7) 
C21 0.0175(9) 0.0231(9) 0.0191(9) 0.0062(7) 0.0045(7) 0.0062(7) 
C22 0.0168(9) 0.0228(9) 0.0179(9) 0.0041(7) 0.0029(7) 0.0083(7) 
C23 0.0168(9) 0.0189(9) 0.0183(9) 0.0038(7) 0.0021(7) 0.0065(7) 
C24 0.0217(9) 0.0264(9) 0.0262(10) 0.0071(8) 0.0091(7) 0.0121(8) 
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Table 11. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å
2
) for 89 
 
x/a y/b z/c U(eq) 
H1A -0.2368 0.2363 0.8992 0.024 
H2A -0.4679 0.1447 0.7571 0.044 
H2B -0.3109 0.1006 0.7110 0.044 
H2C -0.2757 0.2528 0.7471 0.044 
H3A -0.4511 0.0158 0.8687 0.044 
H3B -0.2486 0.0398 0.9376 0.044 
H3C -0.2890 -0.0342 0.8320 0.044 
H4A 0.1017 0.0955 0.9782 0.025 
H5A 0.4308 0.2090 1.0593 0.043 
H5B 0.4515 0.3115 0.9975 0.043 
H5C 0.4158 0.1615 0.9519 0.043 
H6A 0.1696 0.2558 1.1171 0.044 
H6B -0.0331 0.2379 1.0509 0.044 
H6C 0.1585 0.3615 1.0605 0.044 
H7A 0.0957 0.3673 0.7803 0.036 
H8A 0.4333 0.4924 0.8249 0.039 
H8B 0.3916 0.3400 0.7847 0.039 
H8C 0.4632 0.4035 0.8930 0.039 
H9A 0.2009 0.5655 0.8910 0.068 
H9B 0.1929 0.4878 0.9692 0.068 
H9C -0.0039 0.4658 0.8968 0.068 
H10 0.099(3) -0.049(2) 0.8499(15) 0.021(5) 
H11 0.134(4) -0.188(3) 0.7145(18) 0.045(7) 
H12 0.112(3) -0.075(2) 0.5890(16) 0.023(5) 
H14 -0.013(3) 0.2203(18) 0.6587(13) 0.012(4) 
H16A 0.029(3) 0.3483(19) 0.5541(13) 0.017(5) 
H16B 0.132(3) 0.320(2) 0.4796(16) 0.029(6) 
H18 0.182(4) 0.584(2) 0.6508(16) 0.034(6) 
H19 0.527(3) 0.735(2) 0.7340(17) 0.034(6) 
H20 0.760(4) 0.619(2) 0.6954(16) 0.036(6) 
H22 0.409(3) 0.284(2) 0.4637(14) 0.017(5) 
H23A 0.250(3) 0.0863(19) 0.4972(14) 0.013(5) 
H23B 0.376(3) 0.130(2) 0.5943(15) 0.020(5) 
H24A 0.7052 0.2416 0.4541 0.035 
H24B 0.5215 0.1074 0.4243 0.035 
H24C 0.6646 0.1511 0.5239 0.035 
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APPENDIX B 
X-RAY CRYSTAL DATA FOR RAC-(3S, 4R)-1-BENZYL-3-METHYL-4-PHENYL-1-
ANONIABICYCLO[3.1.0]HEXANE HEXAFLUOROANTIMONATE (V) 194 
 
Figure 15. X-ray crystal structure of 194 
 
ORTEP structure of rac-(3S,4R)-1-benzyl-3-methyl-4-phenyl-1-azoniabicyclo[3.1.0]hexane 
hexafluoroantimonate (V).  The molecular structure is drawn with 50% probability displacement 
ellipsoids; hydrogen atoms are drawn with an artificial radius.  
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Table 12. Crystallographic Information for Compound 194 
Identification code perez2 
Chemical formula C19H22F6NSb 
Formula weight 500.12 
Temperature 150(2) K 
Wavelength 1.54178 Å 
Crystal size 0.020 x 0.080 x 0.180 mm 
Crystal habit translucent colourless plate 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 10.3372(2) Å α = 62.3680(7)° 
 
b = 10.4889(2) Å β = 78.1060(7)° 
 
c = 10.5185(2) Å γ = 81.1370(8)° 
Volume 986.45(3) Å
3
 
 
Z 2 
Density (calculated) 1.684 g/cm
3
 
Absorption coefficient 11.634 mm
-1
 
F(000) 496 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus, Cu 
Theta range for data 
collection 
4.38 to 68.23° 
Index ranges -12<=h<=12, -12<=k<=11, -12<=l<=12 
Reflections collected 18064 
Independent reflections 3519 [R(int) = 0.0208] 
Coverage of independent 
reflections 
97.3% 
Absorption correction multi-scan 
Max. and min. transmission 0.8010 and 0.2290 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2013 (Sheldrick, 2013) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 3519 / 0 / 332 
Goodness-of-fit on F2 0.828 
Δ/σmax 0.002 
Final R indices 
3438 data; 
I>2σ(I) 
R1 = 0.0185, wR2 = 
0.0588 
 
all data R1 = 0.0189, wR2 = 
 100 
0.0596 
Weighting scheme 
w=1/[σ2(Fo
2
)+(0.0680P)
2
] 
where P=(Fo
2
+2Fc
2
)/3 
Largest diff. peak and hole 0.772 and -0.331 eÅ
-3
 
R.M.S. deviation from mean 0.057 eÅ
-3
 
  
Table 13. Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) for 194 
 
x/a            y/b z/c U(eq) 
Sb1 0.76125(2) 0.74101(2) 0.54529(2) 0.02610(7) 
F1 0.87160(16) 0.87272(19) 0.5333(2) 0.0559(4) 
N1 0.72392(16) 0.31645(18) 0.38418(17) 0.0266(3) 
C1 0.7429(3) 0.4648(2) 0.3614(2) 0.0383(5) 
F2 0.81830(16) 0.78801(18) 0.34871(15) 0.0472(3) 
C2 0.6479(2) 0.3751(2) 0.4864(2) 0.0298(4) 
F3 0.62455(15) 0.88699(17) 0.49326(18) 0.0480(3) 
C3 0.6930(2) 0.2843(2) 0.6344(2) 0.0280(4) 
F4 0.64894(16) 0.61089(17) 0.55656(19) 0.0511(4) 
C4 0.75965(19) 0.1454(2) 0.6243(2) 0.0280(4) 
F5 0.70185(19) 0.6912(2) 0.74115(17) 0.0599(4) 
C5 0.8210(2) 0.1989(3) 0.4649(2) 0.0321(5) 
F6 0.89949(16) 0.59694(17) 0.59171(17) 0.0495(4) 
C6 0.8590(2) 0.0652(3) 0.7289(2) 0.0365(4) 
C7 0.5856(2) 0.3127(2) 0.8579(2) 0.0325(4) 
C8 0.4827(2) 0.2912(3) 0.9732(2) 0.0366(5) 
C9 0.3766(2) 0.2152(2) 0.9931(2) 0.0364(4) 
C10 0.3714(2) 0.1608(2) 0.8964(2) 0.0365(4) 
C11 0.4739(2) 0.1831(2) 0.7805(2) 0.0336(4) 
C12 0.58089(18) 0.2589(2) 0.76029(19) 0.0282(4) 
C13 0.65653(19) 0.2998(2) 0.2808(2) 0.0303(4) 
C14 0.7907(2) 0.1563(2) 0.1585(2) 0.0347(4) 
C15 0.8851(2) 0.1435(3) 0.0498(3) 0.0411(5) 
C16 0.9458(2) 0.2646(3) 0.9397(3) 0.0454(6) 
C17 0.9100(2) 0.3973(3) 0.9393(2) 0.0424(5) 
C18 0.8150(2) 0.4099(2) 0.0480(2) 0.0351(4) 
C19 0.75597(18) 0.2890(2) 0.15932(19) 0.0280(4) 
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Table 14. Bond lengths [Å] and angles [°] for 194 
Sb1-F5 1.8637(15)   
Sb1-F6 1.8712(14)   
Sb1-F2 1.8728(14)   
N1-C13 1.492(2)   
N1-C1 1.499(3)   
C1-C2 1.477(3)   
C1-H1A 0.99(3)   
C2-H2 0.93(2)   
C3-C4 1.553(3)   
C4-C6 1.521(3)   
C4-H4 0.93(2)   
C5-H5B 1.02(3)   
C6-H6B 0.91(3)   
C7-C8 1.393(3)   
C7-H7 0.98(2)   
C8-H8 0.95(3)   
C9-H9 0.95(2)   
C10-H10 0.99(3)   
C11-H11 0.98(3)   
C13-H13A 0.93(2)   
C14-C19 1.387(3)   
C14-H14 0.85(3)   
C15-H15 0.94(3)   
C16-H16 0.93(3)   
C17-H17 0.95(3)   
C18-H18 0.94(3) 
  
Sb1-F1 1.8683(15) 
Sb1-F4 1.8725(14) 
Sb1-F3 1.8750(14) 
N1-C5 1.499(3) 
N1-C2 1.506(2) 
C1-H1B 0.92(3) 
C2-C3 1.528(3) 
C3-C12 1.518(3) 
C3-H3 0.92(2) 
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C4-C5 1.525(3) 
C5-H5A 0.92(3) 
C6-H6A 0.96(3) 
C6-H6C 0.97(3) 
C7-C12 1.393(3) 
C8-C9 1.379(3) 
C9-C10 1.391(3) 
C10-C11 1.394(3) 
C11-C12 1.385(3) 
C13-C19 1.503(3) 
C13-H13B 1.00(2) 
C14-C15 1.385(3) 
C15-C16 1.389(4) 
C16-C17 1.381(4) 
C17-C18 1.389(3) 
C18-C19 1.385(3) 
F5-Sb1-F1 90.87(9)   
F1-Sb1-F6 90.03(8)   
F1-Sb1-F4 179.27(5)   
F5-Sb1-F2 178.66(6)   
F6-Sb1-F2 88.85(7)   
F5-Sb1-F3 90.42(8)   
F6-Sb1-F3 178.40(5)   
F2-Sb1-F3 89.56(7)   
C13-N1-C1 119.34(16)   
C13-N1-C2 120.78(16)   
C1-N1-C2 58.92(13)   
C2-C1-H1B 118.8(16)   
C2-C1-H1A 118.5(15)   
H1B-C1-H1A 116.(2)   
C1-C2-C3 119.52(19)   
C1-C2-H2 118.0(13)   
C3-C2-H2 120.5(14)   
C12-C3-C4 114.77(17)   
C12-C3-H3 109.6(15)   
C4-C3-H3 110.9(15)   
C6-C4-C3 113.13(17)   
C6-C4-H4 112.2(15)   
 103 
C3-C4-H4 106.2(14)   
N1-C5-H5A 109.4(17)   
N1-C5-H5B 106.8(15)   
H5A-C5-H5B 114.(2)   
C4-C6-H6B 110.4(18)   
C4-C6-H6C 111.3(15)   
H6B-C6-H6C 107.(2)   
C8-C7-H7 120.3(14)   
C9-C8-C7 120.67(19)   
C7-C8-H8 116.2(16)   
C8-C9-H9 122.6(13)   
C9-C10-C11 119.61(19)   
C11-C10-H10 118.2(15)   
C12-C11-H11 120.1(14)   
C11-C12-C7 119.19(17)   
C7-C12-C3 119.42(17)   
N1-C13-H13A 104.6(15)   
N1-C13-H13B 103.8(13)   
H13A-C13-H13B 108.(2)   
C19-C14-H14 119.(2)   
C14-C15-C16 120.0(2)   
C16-C15-H15 119.5(16)   
C17-C16-H16 120.6(18)   
C16-C17-C18 120.6(2)   
C18-C17-H17 115.8(18)   
C19-C18-H18 120.6(18)   
C14-C19-C18 119.10(18)   
C18-C19-C13 120.95(18) 
  
F5-Sb1-F6 91.18(7) 
F5-Sb1-F4 89.15(8) 
F6-Sb1-F4 90.70(8) 
F1-Sb1-F2 90.47(8) 
F4-Sb1-F2 89.51(8) 
F1-Sb1-F3 89.86(7) 
F4-Sb1-F3 89.41(7) 
C13-N1-C5 119.34(16) 
C5-N1-C1 116.07(17) 
C5-N1-C2 107.47(15) 
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C2-C1-N1 60.78(13) 
N1-C1-H1B 114.9(15) 
N1-C1-H1A 115.9(15) 
C1-C2-N1 60.30(13) 
N1-C2-C3 107.75(17) 
N1-C2-H2 112.6(14) 
C12-C3-C2 112.96(17) 
C2-C3-C4 103.24(16) 
C2-C3-H3 104.8(14) 
C6-C4-C5 113.60(16) 
C5-C4-C3 103.85(16) 
C5-C4-H4 107.2(14) 
N1-C5-C4 104.42(15) 
C4-C5-H5A 112.4(17) 
C4-C5-H5B 109.6(15) 
C4-C6-H6A 113.2(16) 
H6A-C6-H6B 110.(2) 
H6A-C6-H6C 105.(2) 
C8-C7-C12 119.92(19) 
C12-C7-H7 119.8(14) 
C9-C8-H8 123.1(16) 
C8-C9-C10 119.76(18) 
C10-C9-H9 117.6(13) 
C9-C10-H10 122.2(15) 
C12-C11-C10 120.85(18) 
C10-C11-H11 119.0(14) 
C11-C12-C3 121.40(17) 
N1-C13-C19 110.67(15) 
C19-C13-H13A 113.9(15) 
C19-C13-H13B 114.8(13) 
C19-C14-C15 120.8(2) 
C15-C14-H14 120.(2) 
C14-C15-H15 120.4(16) 
C17-C16-C15 119.4(2) 
C15-C16-H16 120.0(18) 
C16-C17-H17 123.6(18) 
C19-C18-C17 120.2(2) 
C17-C18-H18 119.1(18) 
 105 
C14-C19-C13 119.94(18) 
 
Table 15. Anisotropic atomic displacement parameters (Å
2
) for 194 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k 
a
*
 b
*
 U12 ] 
U11 U22 U33 U23 U13 U12 
Sb1 0.02633(10) 0.02878(10) 0.02405(10) -0.01374(7) -0.00199(6) -0.00028(6) 
F1 0.0438(8) 0.0568(10) 0.0858(12) -0.0444(9) -0.0128(8) -0.0095(7) 
N1 0.0277(8) 0.0315(8) 0.0191(7) -0.0122(6) -0.0004(6) 0.0007(6) 
C1 0.0551(13) 0.0333(11) 0.0247(10) -0.0139(9) 0.0031(9) -0.0075(9) 
F2 0.0513(9) 0.0566(9) 0.0267(6) -0.0166(6) 0.0005(6) 0.0004(7) 
C2 0.0335(11) 0.0323(10) 0.0245(9) -0.0165(8) 0.0006(8) 0.0013(7) 
F3 0.0364(7) 0.0456(8) 0.0552(9) -0.0209(7) -0.0064(6) 0.0103(6) 
C3 0.0281(10) 0.0336(11) 0.0235(10) -0.0146(8) -0.0008(8) -0.0037(8) 
F4 0.0523(9) 0.0443(8) 0.0629(10) -0.0271(7) -0.0038(7) -0.0169(7) 
C4 0.0275(9) 0.0338(10) 0.0227(9) -0.0135(8) -0.0033(7) -0.0002(8) 
F5 0.0738(11) 0.0751(12) 0.0289(7) -0.0284(7) -0.0001(7) 0.0073(9) 
C5 0.0292(11) 0.0427(13) 0.0254(11) -0.0183(9) -0.0060(8) 0.0076(9) 
F6 0.0507(8) 0.0482(9) 0.0458(8) -0.0222(7) -0.0140(7) 0.0205(7) 
C6 0.0352(11) 0.0455(13) 0.0251(11) -0.0134(9) -0.0082(8) 0.0042(9) 
C7 0.0317(10) 0.0405(12) 0.0269(10) -0.0166(8) -0.0035(8) -0.0031(8) 
C8 0.0414(12) 0.0485(13) 0.0238(10) -0.0212(9) -0.0037(8) 0.0012(9) 
C9 0.0332(10) 0.0474(12) 0.0215(9) -0.0131(8) 0.0042(8) -0.0014(8) 
C10 0.0339(10) 0.0456(12) 0.0269(10) -0.0136(8) 0.0005(8) -0.0095(9) 
C11 0.0341(10) 0.0426(11) 0.0261(9) -0.0175(8) -0.0021(8) -0.0039(8) 
C12 0.0297(9) 0.0324(10) 0.0201(8) -0.0108(7) -0.0031(7) 0.0004(7) 
C13 0.0287(9) 0.0385(11) 0.0228(9) -0.0137(8) -0.0048(8) 0.0012(8) 
C14 0.0414(11) 0.0346(11) 0.0258(9) -0.0117(8) -0.0075(8) 0.0016(8) 
C15 0.0445(12) 0.0478(14) 0.0368(11) -0.0266(10) -0.0102(9) 0.0117(10) 
C16 0.0337(11) 0.0763(18) 0.0315(11) -0.0321(11) -0.0011(9) 0.0032(11) 
C17 0.0412(12) 0.0568(14) 0.0255(10) -0.0155(9) 0.0017(9) -0.0118(10) 
C18 0.0417(11) 0.0391(12) 0.0243(9) -0.0147(8) -0.0037(8) -0.0022(8) 
C19 0.0279(9) 0.0372(10) 0.0198(8) -0.0137(7) -0.0069(7) 0.0025(7) 
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Table 16. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å
2
) for 194 
x/a y/b z/c U(eq)  
H1B 0.711(2) 0.539(3) 0.282(3) 0.036(6) 
H1A 0.829(3) 0.478(3) 0.380(3) 0.042(7) 
H2 0.558(2) 0.394(2) 0.479(2) 0.025(5) 
H3 0.755(2) 0.337(2) 0.637(2) 0.025(5) 
H4 0.691(2) 0.089(3) 0.641(2) 0.030(5) 
H5A 0.831(3) 0.128(3) 0.435(3) 0.033(7) 
H5B 0.906(3) 0.246(3) 0.446(3) 0.041(6) 
H6A 0.934(3) 0.119(3) 0.709(3) 0.043(7) 
H6B 0.887(3) -0.021(3) 0.729(3) 0.049(7) 
H6C 0.819(2) 0.045(3) 0.828(3) 0.037(6) 
H7 0.662(2) 0.366(2) 0.845(3) 0.031(6) 
H8 0.491(3) 0.331(3) 1.036(3) 0.044(7) 
H9 0.303(2) 0.202(2) 1.068(2) 0.031(5) 
H10 0.297(3) 0.106(3) 0.907(3) 0.038(6) 
H11 0.470(2) 0.144(3) 0.713(3) 0.035(6) 
H13A 0.610(2) 0.218(3) 0.338(3) 0.034(6) 
H13B 0.592(2) 0.385(2) 0.250(2) 0.026(5) 
H14 0.756(3) 0.082(3) 0.228(3) 0.060(9) 
H15 0.906(3) 0.054(3) 0.048(3) 0.046(7) 
H16 1.007(3) 0.257(3) -0.135(3) 0.056(8) 
H17 0.946(3) 0.484(3) -0.134(3) 0.052(7) 
H18 0.793(3) 0.501(3) 0.046(3) 0.053(8) 
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